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Cancer is a global health problem and leading cause of deaths 
worldwide. Development of new cancer therapies has prolonged the survival 
of cancer patients, while advances in molecular biology and genetics have 
given insights into the pathogenesis of cancers. Cancer is caused by 
accumulation of genetic alterations, including gene mutations, copy number 
variation, and epigenetic alterations including DNA methylation and histone 
modifications. Understanding the specific alterations in different cancer types 
can provide a molecular classification system that may help to improve tumor 
diagnosis, prognostication and therapy.  
In the present thesis, we set out to harness the power of whole exome 
sequencing to identify and characterize somatic alterations in cancer genomes. 
We first seek to identify new driver events in gastrointestinal stromal tumor 
(GIST), explore their molecular consequences and test their utility as 
prognostic markers. To this end, we performed whole-exome sequencing on 
18 GIST tumor samples from 14 patients, followed by targeted sequencing of 
3 candidate cancer genes from an independent 109 GIST samples. Statistical 
approach was employed in order to prioritize novel significantly mutated 
genes in the tumor cohort. We identified for the first time, recurrent SETD2 
mutations in GIST samples. In our dataset, SETD2 mutations are identified in 
11.2% of high risk GISTs but 0% of low-risk GISTs. 
SETD2 mutant GISTs exhibited decreased H3K36me3 expression 
while SETD2 silencing promoted DNA damage in GIST-T1 cells, In gastric 
GISTs, SETD2 mutations were associated with overexpression of HOXC 
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cluster genes and a DNA methylation signature of hypomethylated 
heterochromatin. Gastric GISTs with SETD2 mutations or GISTs with 
hypomethylated heterochromatin showed significantly shorter relapse-free 
survival on univariate analysis. These data suggest that assessment of SETD2 
genetic status and epigenomic phenotypes may guide risk stratification in 
GIST patients. 
In the second part of this thesis, we seek to identify potential predictive 
biomarkers for dacomitinib sensitivity in patients with squamous cell 
carcinoma of the head and neck (SCCHN). Whole exome sequencing was 
performed on 18 cisplatin-treated metastatic SCCHN tumors and their 
matched germline DNA.  
Somatic mutations in REV3L, the gene encoding the catalytic subunit 
of DNA polymerase ζ involved in translesional synthesis, are significantly 
enriched in a subset of patients who derived extended clinical benefit to 
dacomitinib. Functional assays showed that loss-of-function of REV3L 
dramatically enhanced the sensitivity of SCCHN cells to dacomitinib by the 
loss of both translesion synthesis and homologous recombination pathways. 
Our data suggest that the inactivation of REV3L may inform treatment 
options in patients of recurrent SCCHN. 
In summary, these studies uses whole exome sequencing along with a 
suite of bioinformatics algorithms to demonstate how analysis of genomic data 
can provide novel biological understanding into previously unknown driver 
events underlying tumor development and progressions. These findings, if 
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independently validated might be subsequently employed as potential 
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Chapter 1 Introduction 
1.1 Gastrointestinal stromal tumor (GIST) 
1.1.1 GIST epidemiology 
GISTs are the most common non-epithelial tumor in the 
gastrointestinal tract, although they constitute only 1 percent of primary 
gastrointestinal tumors (Judson and Demetri 2007). They can occur anywhere 
along the gastrointestinal tract, but are most commonly found in the stomach 
or small intestine (Figure 1.1). Due to the uncertain GIST classification prior 
to 1998, the true frequency is unknown; although population based study in 
Sweden suggested an annual incidence rate of 14.5 cases per million 
population (Nilsson, Bumming et al. 2005). More recent data from Japan 
indicates that the incidence rate for micro-GIST, the pre-malignant form of 
GIST may be much higher (Kawanowa, Sakuma et al. 2006), although further 
study is needed to clarify the relationship between these pre-malignant and 




Figure 1.1 Sites of GIST. Figure taken from National Cancer Institute website: 
http://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq 
The term GIST was first coined to refer to a heterogenous subgroup of 
tumors derived from mesenchymal cells in the gastrointestinal tract (Mazur 
and Clark 1983). GIST was not widely recognized as a separate malignancy 
then, although it has now become evident that GISTs are tumors of the 
interstitial cells of Cajal (ICCs) or their precursors (Kindblom, Remotti et al. 
1998). The ICCs are the ‘pacemaker cells’ of the gastrointestinal tract that 
creates electrical potential leading to contraction of the smooth muscle. They 
share some similarities with GIST cells, for instance both normal ICCs and 
malignant GIST cells exhibit overexpression of KIT.  
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It was subsequently shown that activating mutation in KIT is a 
pathogenic event driving the development of GIST (Hirota, Isozaki et al. 
1998). It is now recognized that 70-80% of GISTs harbours a KIT gene 
mutation and 90% of GISTs overexpress the KIT protein, providing a crucial 
diagnostic marker for this malignancy. KIT is a member of the type III 
receptor tyrosine kinase family that include platelet-derived growth factor 
receptor-alpha (PDGFRA). GISTs that do not harbour KIT mutations may 
harbour mutations in PDGFRA instead (Heinrich, Corless et al. 2003). 
Facilitated by KIT or PDGFRA mutations, ICC cells may form micro-GIST 
nodules measuring less than 1 cm and showing very low mitotic activity. 
Additional mutations and chromosomal changes are required for micro-GIST 
to progress into clinically significant GISTs (Figure 1.2).  
 
Figure 1.2 Model of GISTs origin and progression. In the United States, 
micro-GIST prevalence is conservatively estimated to be more than 10 million 
lesions. Of these only 5000 progresses into clinical GIST and about 2000 are 




In normal cells, the KIT ligand, stem cell factor (SCF) binds to the KIT 
causing the homodimerization of the extracellular receptor and activation of 
the intercellular kinase domain (Huang, Nocka et al. 1990) (Figure 1.3). In 
contrast KIT mutation in GIST cells lead to constitutive activation of the 
kinase without binding to the ligand. These mutations disrupt the normal 
KIT/PDGFRA juxtamembrane domains and prevent the kinase activation loop 
from swinging into active conformations. Similar mechanisms had been 
observed for PDGFRA mutations in GISTs. Currently KIT and PDGFRA 
mutations are the only known driving events in large fraction of GIST 
patients. Few studies have addressed the possibility of the existence of 






Figure 1.3 KIT and PDGFRA structure and mutation. Mutations in the 
juxtamembrane domain (shown in red), which is encoded by exon 11 
of KIT or by exon 12 of PDGFRA, allow receptor dimerization in the absence 
of ligand, thus resulting in a conformational change that relieves the 
suppression of the activation loop (shown in green) of the kinase domain. 
Figure taken from (Corless, Barnett et al. 2011). 
 
1.1.2 Clinical practise in GIST management 
Surgery remains the primary treatment of GISTs, with approximately 
60% of patients ‘cured’ by surgery alone (Joensuu, Eriksson et al. 2012) 
(Figure 1.4). Prior to 2000, treatment options for GISTs were limited. 
Radiation and chemotherapy were considered as the only treatment options for 
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GIST patients with unresectable or metastatic tumors even though response 
rate are poor (<10%) (Dematteo, Heinrich et al. 2002). In the early 1990s, the 
tyrosine kinase inhibitor, imatinib was first developed as a therapy for chronic 
myelogenous leukaemia (CML). CML was characterized by the formation of 
the fusion oncoprotein BCR-ABL, which shares significant structural 
similarities with the kinase domains found in KIT and PDGFRA. In-vitro 
experiments in the laboratory showed imatinib can inhibit the growth of KIT-
mutant GISTs (Tuveson, Willis et al. 2001). This led to the first clinical use of 




Figure 1.4: Treatment options for GISTs. Figure obtained from National 





Inhibition of activated KIT or PDGFRA with tyrosine kinase inhibitors 
has a dramatic effect on GIST patients’ survival. Imatinib is the first line 
option of unresectable or recurrent GISTs, with a primary response rate of 
more than 80% (Demetri, von Mehren et al. 2002). However, resistance to 
treatment with TKIs is common in GISTs, with the vast majority of patients 
developing a secondary resistance within 24 months of therapy. For these 
patients, additional TKIs such as sunitinib (Demetri, van Oosterom et al. 2006) 
and regorafenib (Demetri, Reichardt et al. 2013) can act as second and third 
line therapy after the failure of imatinib.  
Imatinib is also used as an adjuvant treatment after surgery to reduce 
the risk of tumor recurrence (Dematteo, Ballman et al. 2009). In this setting, 
risk classification plays an important role in deciding the population of 
patients that needs to be treated with adjuvant imatinib. Due to the 
heterogeneity in patients outcome after surgery, some patients require 
additional treatment after surgical procedures, while others will not experience 
tumor recurrence and therefore do not have to undergo further expensive and 
toxic treatments. 
The clinicopathological features of GIST that may affect prognosis are 
an active area of research. Based on retrospective studies of clinical records 
from the time periods that predated the use of imatinib, several features 
predictive of risk of recurrence had been identified. These features include 
tumor size, mitotic rate, site of tumor origin and presence of tumor rupture. An 
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example of commonly used classification system is the modified NIH 
classification (Joensuu classification) shown in Table 1.1. 
Table 1.1 Joensuu’s modification of the consensus NIH classification for 
selecting GIST patients for adjuvant therapy. Table adapted from (Joensuu 
2008). 
 
However, current risk stratification methods are based on 
clinicopathological features and have its limitations, especially with regards to 
patients with intermediate risk profile. Therefore, there is an urgent need to 
find additional features that distinguish between the two groups of patients.  
1.1.3 The role of molecular features in GIST management 
Currently, most of the molecular studies in GIST focus on KIT and 
PDGFRA. Mutations in several other genes such as BRAF, KRAS, PIK3CA, 
and SDH complex had also been reported. However, none of these occurs in 
more than 2% of GISTs. Since very few studies had comprehensively 
catalogued the mutational profile of GISTs in an unbiased manner, it is 
possible that additional mutational events that may carry prognostic 
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information in GIST had not been discovered to date. In addition while KIT or 
PDGFRA mutation may set the initial course of a GIST, additional mutational 
events may be needed to drive tumor progression from low-risk to high-risk 
GISTs. Therefore, knowledge of the complete genetic factors leading to 
different outcome in GIST patients is currently lacking. 
Emerging data also provide evidence that the exact type of KIT or 
PDGFRA mutations may carry prognostic information and is predictive of 
GIST sensitivity to targeted therapy.  Gastric GISTs with exon 9 duplication 
or exon 11 deletion involving codon 557 and/or 558 are associated with 
shorter disease-free survival while PDGFRA exon 18 mutations are associated 
with better prognosis (Wozniak, Rutkowski et al. 2014) (Figure 1.5a). Exon 
11-mutant KIT is also highly sensitive to imatinib whereas exon 9-mutant KIT 
and wildtype KIT and most PDGFRA mutant GISTs are less sensitive to the 
drug. In contrast, the most common PDGFRA mutation, D842V is fully 
resistant to imatinib and do not benefit from adjuvant therapy (Corless, 




Figure 1.5 Relationship between KIT genotypes and recurrent-free survival 
and response to imatinib treatment. (a) Effect of genotype on recurrence-free 
survival in the placebo group. (b) Relationship between KIT exon 11 mutation 








1.2 Squamous cell carcinoma of the head and neck (SCCHN) 
1.2.1 SCCHN epidemiology 
SCCHNs are the sixth most common cancer worldwide with 
approximately 600,000 new cases diagnosed per year (Ferlay, Soerjomataram 
et al. 2015). Only 40-50% of patients with SCCHN will survive for 5 years 
(Leemans, Braakhuis et al. 2011). SCCHN generally begins in the squamous 
cells that line the mucosal surfaces of the head and neck. The most frequent 
tumor sites of SCCHN are the larynx, the pharynx and the oral cavity (Figure 
1.6).  
 




 The most important risk factors identified thus far are tobacco use and 
alcohol consumption. About 75% of SCCHN are attributable to tobacco and 
alcohol use (Blot, McLaughlin et al. 1988) and the effects of tobacco and 
alcohol appears to be synergistic (Blot, McLaughlin et al. 1988, Tuyns, Esteve 
et al. 1988). A subset of SCCHN that involve the tonsils or the base of the 
tongue is caused by infection with high-risk types of human papillomavirus 
(HPV-16) (Chaturvedi, Engels et al. 2011). In parts of Asia, betel-quid 
chewing had also been shown to play a role in the development of SCCHN 
(Chen, Chang et al. 2008).  
1.2.2 Clinical practise in SCCHN management 
The mainstays of treatments for early and locoregionally advanced 
SCCHN are surgery combined with postoperative radiotherapy. Despite this 
aggressive multimodality therapy, more than half of the patients will develop 
locoregional or distant recurrence within 2 years (Marur and Forastiere 2008). 
For patients with recurrent and/or metastatic (R/M) SCCHN, survival 
outcomes remain dismal with a median survival of 6-10 months (Forastiere, 
Leong et al. 2001, Gibson, Li et al. 2005). Platinum-based combination 
chemotherapy is the backbone of palliative treatment for these patients 
although clinical benefit is modest. 
Cetuximab, an anti-EGFR monoclonal antibody is an approved 
treatment option for R/M-SCCHN either as single agent (Vermorken, Trigo et 
al. 2007) or in combination with chemotherapy (Figure 1.7A) (Vermorken, 
Mesia et al. 2008). Cetuximab as a single agent demonstrated an objective 
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response rate of 13% with median duration of approximately 4 months in R/M 
SCCHN that progressed on platinum therapy (Vermorken, Trigo et al. 2007). 
The same success has not observed with EGFR targeting tyrosine kinase 
inhibitors such as gefitinib and erlotinib (Hansen and Siu 2013). The addition 
of these two targeted agents had failed to show efficacy in two different trials 
of R/M SCCHN (Figure 1.7B) (Argiris, Ghebremichael et al. 2013, Martins, 
Parvathaneni et al. 2013). More recently, the use of afatinib, a second-
generation EGFR-TKI that irreversibly blocks multiple HER family receptors 
had been associated with increased progression-free survival, compared with 
methotrexate (median 2.6 versus 1.7 months, HR 0.80, 95% CI 0.65-0.98) 
(Figure 1.7C) (Machiels, Haddad et al. 2015). Dacomitinib, another HER 
family blocker is also currently being examined in SCCHN after showing an 
objective response rate of 20.8% and progression-free survival of 3.9 months 





Figure 1.7: Kaplan-Meier estimates of progression free survival in R/M 
SCCHN according to treatment group. (A)  Chemotherapy plus cetuximab vs 
chemotherapy alone. (B) Gefitinib plus chemotherapy vs chemotherapy alone. 
(C) Afitinib vs chemotherapy. Figure modified from (Vermorken, Mesia et al. 





1.2.3 The role of molecular features in SCCHN management 
Comprehensive whole exome sequencing of primary SCCHN tumors 
had been previously reported (Agrawal, Frederick et al. 2011, Stransky, Egloff 
et al. 2011, Cancer Genome Atlas 2015). These studies demonstrate that the 
majority of driver mutations in SCCHN occur as inactivating mutation in 
tumor suppressor genes such as TP53, CDKN2A and NOTCH1. 
Disappointingly, activating mutations in oncogenes which are more readily 
targetable are rare. Of the 15 most frequently mutated genes in SCCHN (Table 
1.2), only 2 (HRAS and PIK3CA) are oncogenes, and only PIK3CA is 












Table 1.2: Commonly mutated genes in SCCHN exome sequencing studies. 
Table taken from (Kang, Kiess et al. 2015). 
 
*Abbreviations: NA, not available; TCGA, The Cancer Genome Atlas; TSG, 
tumor suppressor genes 
 
Beyond genetic alterations, biomarkers for SCCHN can also be 
identified by gene expression profile. In this regard, EGFR is almost 
universally expressed in SCCHN and its overexpression is correlated with 
poor prognosis (Hansen and Siu 2013), making it an attractive molecular 
target in this malignancy. Epidermal growth factor receptor (EGFR/HER1) is 
a transmembrane tyrosine kinase receptor belonging to HER family receptors 
(EGFR/HER1, HER2, HER3, HER4). When activated by binding to its ligand, 
EGFR homodimerizes or heterodimerizes with other member of the HER 
family, stimulating its tyrosine kinase activity and leading to 
autophosphorylation of tyrosine residues in its cytoplasmic tail. This can lead 
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to activation of downstream signalling cascades including RAS/RAF/MAPK, 
PI3K/AKT/mTOR and JAK/STAT (Figure 1.6). 
 
Figure 1.8: EGFR signalling pathways. Figure adapted from (Chong and Janne 
2013) 
 
Therefore, it is not surprising that EGFR-targeted agents have been 
extensively studied in SCCHN and these include cetuximab (an anti-EGFR 
antibody), gefitinib/erlotinib (selective EGFR inhibitors), and 
afatinib/dacomitinib (irreversible pan-HER inhibitors) (Figure 1.8). However, 
the clinical benefit of these targeted agents is typically modest with reported 
response rate of 1.4%–20.8% and progression-free survival of 1.8–3.9 months 
(Soulieres, Senzer et al. 2004, Vermorken, Trigo et al. 2007, Stewart, Cohen et 
al. 2009, Abdul Razak, Soulieres et al. 2013, Kim, Kwon et al. 2015). 
Therefore, there is a pressing need to identify molecular predictors to evaluate 
the efficacy of EGFR inhibitors in order to maximize the clinical benefit of 
EGFR inhibitors. Comprehensive molecular profiling such as whole exome 
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sequencing may provide further opportunities to characterize the subset of 
patients who derive the most benefit from EGFR inhibitors. 
1.3  Thesis objectives 
In this thesis, we aim to identify molecular features that can be utilized 
as biomarkers for GIST and R/M SCCHN patients. Identification of molecular 
differences between cancer patients with differing clinical outcomes may 
allow for accurate patient selection for the appropriate therapy. The present 
study is focused on the identification of predictive and prognostic biomarkers 
using whole exome sequencing. This next generation sequencing technique 
had been shown to be a powerful new approach to identify important 
pathogenic events driving tumorigenesis, and can potentially accelerate new 
discovery in cancer biology.  
The specific aims of this project are 
1. To identify the genetic difference between low-risk and high-risk GIST 
2. To explore the molecular consequences of these differences in GIST 
3. To test the utility of the genetic difference as prognostic markers in 
GIST 
4. To identify potential predictive biomarkers for dacomitinib sensitivity 






In this chapter, we have provided a literature review encompassing the 
historical background, current clinical practises and roles of molecular 
subtyping in GIST and SCCHN. In subsequent chapters, this thesis will focus 
on the use of next generation technologies to archive the full catalogues of 
exome-wide somatic mutational events in these malignancies. The 
experimental and computational approaches involved in identification and 
validation of novel driver events will be discussed. Possible mechanisms 
whereby mutational event may affect clinical outcomes in GIST and SCCHN 




Chapter 2 Materials and Methods 
2.1 Introduction 
The initiation and progression of cancer is characterized by 
accumulation of somatic genetic and epigenetic aberrations. Next generation 
sequencing (NGS) represents an effective way to identify these genetic 
aberrations in cancer genomes. The NGS methods are similar in principle to 
the traditional capillary electrophoresis sequencing. In both methods, bases of 
a small fragment of DNA are sequentially identified from signals emitted 
while each fragment is re-synthesized from a DNA template strand (Figure 
2.1). However, unlike the capillary electrophoresis-based methods, NGS 
platforms perform sequencing of millions of small DNA fragment in parallel. 
This advance had enabled rapid sequencing of large stretches of DNA, 
resulting in significant time and cost savings. 
 
 
Figure 2.1: Concepts of next generation sequencing. (A) Extracted genomic 
DNA. (B) DNA fragmentation and adapter ligation. (C) Parallel sequencing. 
(D) Alignment to reference genome. (E) Sequence data is derived from the 






Next generation sequencing technologies have enabled a wide range of 
protocols to measure the genome, transcriptome and epigenome of individual 
cells. Exome sequencing is one of the most commonly used NGS methods.  In 
exome sequencing, the protein-coding portion of the genome is selectively 
captured using standard library preparation kits and sequenced. While this 
portion makes up less than 2% of the total human genome, it contains ~85% of 
known disease-related variants, therefore providing a cost-effective strategy to 
identify causal genetic variants for the cancer phenotype of interest.  
In this thesis, we will attempt to utilize the advantages afforded by 
whole exome sequencing to identify novel genetic alteration in GISTs and 
R/M SCCHN that contribute to tumor phenotypes. In addition, a series of 
computational and experimental procedures were performed in order to show 
that these genetic alterations can exert a measurable phenotypic effect and 
affect malignant potentials in cancer tissues.  
An overview of the overall strategy employed in this thesis is outlined 
here. The rest of this chapter provide a detailed description of each of these 
procedures. 
 
2.1.1 Whole exome sequencing of paired tumor-normal samples 
 Genomic DNA from the tumor and matched blood samples were 
obtained from patients with different clinical characteristics. Genomic DNA 
was then sheared to a library of small fragments. The fragments were 
hybridized to biotinylated DNA or RNA baits in order to enrich for the exonic 
region of the genome. Lastly the hybridized fragments were recovered, 
amplified and subjected to next generation sequencing. 
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2.1.2 Bioinformatics processing to identify somatic alterations 
After acquiring the exome sequencing data, bioinformatics algorithm 
were employed to map DNA sequences to the reference genome and catalogue 
the list of somatic mutations in each tumor. Further processing was conducted 
to identify a catalogue of high-confidence somatic alterations. An orthogonal 
method was employed to validate a subset of these alterations to ensure a high 
quality dataset for downstream analysis. 
 
2.1.3 Nominate and characterize somatic alterations underlying cancer 
phenotypes 
 Having secured high quality datasets, significantly mutated genes were 
identified in order to provide insights and generate hypothesis into processes 
that give rise to cancer tissues with differing clinical outcomes. Finally, 
functional studies were designed and performed to better understand the 
impact of genetic variants on cancer phenotypes. 
 
2.2  GIST 
 
2.2.1 Patient samples 
GIST samples were obtained from the SingHealth Tissue Repository, 
with informed patient consent. Exome sequencing was performed on 18 GIST 
samples and matched normal blood samples from 14 affected individuals. For 
one patient, primary and metastatic tumours were sequenced (HR4), and for 
three patients (HR1, HR5 and HR8) two metastatic tumours (but no primary 
tumours) were sequenced. For prevalence analysis, the coding regions of KIT, 
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PDGFRA and SETD2 were resequenced in 83 high-risk/metastatic tumours, 29 
low/intermediate-risk tumours and 13 GISTs of unknown risk classification 
(due to incomplete pathology information). 
 
2.2.2 Whole exome sequencing 
DNA fragmentation, library preparation and exome capture of the 
genomic DNA of GIST and matched blood samples were performed according 
to manufacturer's instructions. Exome capture was performed using the 
SureSelect Human All Exon Kit V.3 (Agilent Technology, California, USA) 
or Truseq v1 (Illumina). All samples were sequenced on a Hiseq2000 
(Illumina) sequencer.  
 
2.2.3 Variant calling 
Burrows-Wheeler Aligner (Li and Durbin 2009) was used to align 
sequence reads to the human reference genome National Center for 
Biotechnology Information (NCBI) build 37 (hg19). SAMTools (Li, 
Handsaker et al. 2009) was used to remove PCR duplicates. A previously 
described inhouse Genome Analysis Toolkit (GATK)-based pipeline 
(McKenna, Hanna et al. 2010) was used to call variants. Somatic mutations 
were inferred by subtracting tumor variants against matched blood variants. 
Variant annotations were performed by comparing discovered variants with 
common variants in dbSNP135 and 1000 Genomes databases and known 
cancer variants in the COSMIC database. Exome sequences have been 
deposited into European Bioinformatics Institute (EBI) Sequence Read 
Archive under accession number PRJEB6401. The significantly mutated gene 
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(SMG) test in the genome MuSiC (Mutational Significance in Cancer) (Dees, 
Zhang et al. 2012) suite was used to identify significantly mutated genes with 
default parameters. All predicted protein-altering mutations were used as input 
for MuSiC. 
 
2.2.4 Sanger sequencing validation 
Having obtained a set of candidate alterations, a subset of the 
discovered variants were subjected to validation with an orthogonal method to 
ensure high quality datasets for subsequent analyses. Sanger sequencing 
primers were designed using Primer3 software. Purified PCR products were 
sequenced in the forward and reverse directions using ABI PRISM BigDye 
Terminator Cycle Sequencing Ready Reaction kits (V.3) and an ABI PRISM 
3730 Genetic Analyzer (Applied Biosystems, California, USA). 
 
2.2.5  Amplicon prevalence sequencing 
Amplicon sequencing refers to a target enrichment method that allows 
for ultra-deep sequencing of a subset of genes or genomic regions in a large 
number of samples. It involves simultaneously amplification and purification 
of thousands of PCR products (amplicon) prior to ultra-deep sequencing. This 
method is useful for screening rare genetic variants in complex samples, such 
tumor tissues with normal contamination. 
Sequencing primers covering the entire protein-coding regions of KIT, 
PDGFRA and SETD2 were designed using Primer3 software. Amplicons were 
generated using a Fluidigm 48×48 Access Array system 
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(http://www.fluidigm.com/access-array-system.html). All samples were 
individually barcoded and sequenced using a Miseq instrument (Illumina). 
 
2.2.6 H3K36me3 immunohistochemistry 
H3K36me3 immunohistochemistry was performed on 4 µm sections of 
formalin-fixed paraffin-embedded patient GIST sections. Briefly, sections 
were microwaved at 98°C for 45 min in target retrieval solution (pH6.0) 
(DAKO) and incubated with H3K36me3 primary antibodies overnight at 4°C 
(1:100, Tri-Methyl-Histone H3 (Lys36) Antibody #9763, Cell Signaling 
Technology, Beverly, Massachusetts, USA). Diaminobenzidine (DAB) 
detection system (DAKO, Denmark) was used according to the manufacturer's 
instructions. Sections were counterstained with haematoxylin, dehydrated and 
mounted. Tumours were classified as H3K36me3 positive with a score of 1 for 
faint or weak staining; 2 for moderate and 3 for strong staining in >25% of 
tumour cells or negative (≤25% tumour cells). 
 
2.2.7 RNA sequencing 
RNA sequencing uses NGS approach to profile transcriptome of 
genomes at higher resolutions than is possible with Sanger sequencing- or 
microarray-based methods, With this method, complementary DNA are 
generated from RNA of interest and sequenced with massively parallelel 
sequencing technologies, followed by mapping of the sequencing reads to the 
genome.  
Two micrograms of total RNA was used to create libraries with 
Illumina TruSeq Stranded Total RNA Kit with Ribo-Zero Gold (Illumina, San 
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Diego, California, USA) according to manufacturer's instructions. Libraries 
were paired-end sequenced for 76 cycles. RNA-seq reads for each sample 
were independently aligned to the human genome (version hg19) using 
TopHat2-2.0.12 (Kim, Pertea et al. 2013). GENCODE V.19 was used as the 
reference transcriptome. The transcript abundance was then estimated by the 
summarizeOverlaps function from the GenomicRanges package (V.1.20.3) 
(Lawrence, Huber et al. 2013) with default parameters. Differential gene 
expression between SETD2 mutant GIST with SETD2 wildtype GIST was 
analysed using the DESeq2 package (Love, Huber et al. 2014), which fits raw 
counts to a negative binomial generalised linear model. The threshold criteria 
to call a significant difference were adjusted p-value<0.1 and an absolute fold 
change greater than 2. 
 
2.2.8 Cell culture 
GIST-T1 cells were purchased from Cosmo Bio, Japan, and cultured 
using the recommended media (Cat.no# PMC-GISTM-COS) according to 
manufacturer's protocols. Media was changed once every 3 days. 
 
2.2.9 Transfection and drug treatment assays 
In each well of a six-well dish, 2×10
5
 cells were seeded. ON-
TARGETplus Human SETD2 (29072) siRNA SMARTpool and ON-
TARGETplus siRNA Non-targeting Pool (Dharmacon, Colorado, USA) were 
used for transfections. A mixture of 3 µL of Dharmafect 1 (Dharmacon, 
Colorado, USA), 10 µL of 20 µM siRNA and 100 µL Optimen were mixed 
together and allowed to stand for 20 min before addition to the cells. For drug 
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treatment experiments, 10 µM of Sunitinib, S-8803 (LC Laboratories, 
Massachusetts, USA) were added to the cells the following day after 




2.2.10 Real-time quantitative RT-PCR 
Total RNAs were extracted using an RNA extraction kit (Qiagen, 
Hilden, Germany). For reverse transcription using a First Strand cDNA 
Synthesis kit (Life Technologies, California, USA) 500 ng RNA was used. 
Equal amounts of cDNA were used for quantitative PCR reactions using 
Standard SYBR Green Master Mix (Life Technologies, California, USA). 
Signals were detected by an ABI 7900HT real-time PCR system (Applied 
Biosystems, Massachusetts, USA). 
 
2.2.11 Western blotting 
For western blotting, cells were lysed using radioimmunoprecipitation 
assay buffer (Sigma-Aldrich, Missouri, USA) in the presence of protease 
inhibitors. Proteins were separated on sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) gels and transferred to nitrocellulose 
membranes. Primary antibodies were applied in wash buffer for 1 h at room 
temperature. Primary antibodies used are antiphospho-Histone H2A.X 
(Ser139) antibody, clone JBW301 (Millipore, Massachusetts, USA) in 1:1000 
dilution and monoclonal anti-β-actin antibody, A5316 (Sigma-Aldrich, 
Missouri, USA) in 1:10 000 dilution. Peroxidase-conjugated secondary 
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antibodies (1:3000) were applied at room temperature for 1 h, and signal was 
visualised using a chemiluminescent substrate (Thermo-Fisher Scientific, 
Massachusetts, USA) followed by exposure to film. 
 
2.2.12 DNA methylation analysis 
Twenty-two GIST tumour samples were subjected to DNA 
methylation profiling. Genomic DNAs were extracted from GIST tissues and 
treated with sodium bisulfite to convert unmethylated cytosines to uracil. 
Bisulfite-converted DNAs were profiled on Illumina Infinium 450k arrays, 
assessing more than 485 000 DNA methylation sites and covering 99% of 
RefSeq gene regions, 96% of cytosine-phospho-guanine (CpG) islands and 
CpG dinucleotides outside of CpG islands. DNA methylation levels were 
extracted and preprocessed using minfi's R package with SWAN 
normalisation 
(http://www.bioconductor.org/packages/release/bioc/html/minfi.html). CpG 
probes with absolute β difference of >0.1 and false discovery rate (FDR) 
adjusted p value <0.05 were considered differentially methylated. DNA 
methylation between SETD2 mutant and SETD2 wildtype GIST and also 
between gastric and intestinal GIST were compared. 
 
2.2.13 Statistical analysis 
Analyses were performed using R statistical packages. Relapse-free 
survival was summarised using Kaplan-Meier curves and compared using log-
rank tests. Univariable and multivariable Cox proportional hazard regression 
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models were used to determine associations between risk factors and relapse 
events. All risk factors were included for multivariate analysis. Two-sided p 
values <0.05 were considered statistically significant. 
 
2.3 SCCHN 
2.3.1 Patient samples 
Tumors and paired peripheral blood samples were collected prior to 
dacomitinib treatment in a prospective phase II trial (NCT01449201) (Kim, 
Kwon et al. 2015). All patients were Koreans. All patients signed consent 
forms for the sample collection and molecular analysis. The study was 
approved by the institutional review board of Severance Hospital, Seoul, 
Korea. All experiments were performed in accordance with relevant 
guidelines. 
 
2.3.2 Whole-exome sequencing 
Board-certified pathologists selected the cases with rich tumor cell 
populations to ensure the selection of regions > 70% tumor purity. For 
genomic DNA extraction, we used the DNeasy Blood & Tissue Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s recommendation. For 
whole-exome sequencing, we used Agilent SureSelect Human All Exome 
50Mb kit (Agilent Technologies). Using 200 ng of DNA, whole exome-
sequencing was performed with Illumina HiSeq2000 platform to generate 150 
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bp paired-end sequencing reads according to the manufacturer's instructions 
(Macrogen, Seoul, South Korea).  
 
2.3.3 Mutation analysis 
To align the sequencing reads onto the reference genome (hg19), we 
used BWA (Burrows Wheeler aligner) based on Burrows-Wheeler 
transformation algorithm (v0.7.5a) using default options (Li and Durbin 2009). 
The local realignment of the sequencing reads were performed using Genome 
Analysis ToolKit (GATK; v3.1.-1) (McKenna, Hanna et al. 2010) with known 
indel lists (Mills_and_1000G_gold_standard.indels.hg19.vcf and 
1000G_phase1.indels.hg19.vcf) as available in GATK bundle datasets 
(ftp.broadinstitute.org). We also used Picard v1.85 
(http://picard.sourceforge.net) and SamTools v0.1.19 to sort the sequencing 
reads in order of genomic coordinates, to remove PCR duplicates and to fix 
the mate information of the paired-end sequence read. Score recalibration of 
the sequencing reads were also performed using GATK with known SNP sites 
(dbsnp_137.hg19.excluding_sites_after_129.vcf).  
In this study, we define mutations as somatic base substitutions (point 
mutations) and indels that are present in the tumor genome but absent in the 
matched normal genomes. By comparing the tumor sequencing reads with 
those of matched normal, we called somatic base substitutions using MuTect 
v1.1.4 (Cibulskis, Lawrence et al. 2013). Somatic base substitutions were 
called using default log odds (LOD) score cutoff of 6.3 and 2.3 for the tumor 
and normal genomes, respectively, instead of predefined cutoffs of sequencing 
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read depth. We used VarScan2 (v2.3.6) to call somatic indels also by 
comparing the sequencing reads of the tumor and matched normal genomes 
(Koboldt, Zhang et al. 2012). To obtain a list of confident indels, we selected 
indels whose allele frequencies are more than 0.2. ANNOVAR (Wang, Li et 
al. 2010) package was used to select the exonic mutations and also to predict 
their functional consequences such as silent or non-silent variants for somatic 
variants. Mutational rate was calculated assuming that the average exome has 
30Mb in protein coding genes with sufficient sequencing coverage. As control, 
we downloaded the somatic mutations of 279 SCCHN (lv2 somatic mutations) 
from the Cancer Genome Atlas consortium (https://tcga-
data.nci.nih.gov/tcga/tcgaDownload.jsp). 
 
2.3.4 Deciphering the mutation signatures 
For mutation signature analysis, we calculated the frequency of coding 
SNVs according to the 3 letter-based 96 trinucleotide classification system, i.e. 
the six mutation categories of base substitutions (C>A, C>G, C>T, T>A, T>C, 
and T>G) were further classified into 96 trinucleotides taking into 
consideration of 5’ and 3’ nucleotides immediate to the mutated base. The 
MatLab code for the mutation signature analysis was downloaded from a 
public resource (http://kr.mathworks.com/matlabcentral/fileexchange/38724-
wtsi-mutational-signature-framework). To obtain the optimal number of 
mutation signatures, we performed permutation tests in which we measured 
the extent of signature stability in a set of 100 simulated cancer genomes by 
increasing the number of signature from one to ten. Stable solution was 
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observed up to five mutation signatures and we annotated five mutation 
signatures by comparing them with the previously reported mutation 
signatures identified from somatic mutations of cancer genomes (Alexandrov, 
Nik-Zainal et al. 2013, Alexandrov, Nik-Zainal et al. 2013). 
 
2.3.5 The analysis of recurrent somatic mutations 
The significantly mutated gene (smg) test in the Genome MuSiC (v0.4) 
suite (Dees, Zhang et al. 2012) was used using the default parameters to 
identify significantly mutated genes. Genes mutated in at least two patients 
and with a false discovery rate (FDR) adjusted convolution test P value of less 
than 0.2 were considered for further analysis. 
 
2.3.6 Reverse transcription PCR and real-time PCR assay 
Expression of REV3L mRNA in the head and neck cancer cells was 
determined by real-time RT-PCR. Total RNA was extracted with 
RNeasy®Mini Kit (Qiagen) from the cell lines, and the initial cDNA strand 
synthesis was performed with SuperScript™ III First-Strand Synthesis 
SuperMix (Invitrogen) followed by kit manual. Real-time PCR was performed 
on Applied Biosystem Step OneTM with SYBR-Green PCR master mix (Life 
Technologies), using foward (5'-GCTCCAGTATGTGTACCATCTTGT) and 
reverse (5'-ATGGATATCTCGAAGTAACACGTC) primer. The expression 
levels of REV3L mRNA for each sample were determined by standardization 





2.3.7 Cell proliferation assay.  
Cellular sensitivity to dacomitinib was determined by the MTT 
cytotoxicity assay. Cells were plated in 96-well plates at 1x103 cells/well and 
allowed to adhere for 24 h, then dacomitinib was added and incubated for 72 
h. The medium was carefully removed and MTT solution was added to each 
well, and plates were incubated for 4 h. The medium was then replaced with 
DMSO, and the results were measured at 540 nm.  
 
2.3.8 Short interfering RNA transfection.  
siRNAs were synthesized to the target sequences of REV3L mRNA 
corresponding to REV3L siRNA #1 (5'-GAUCACAGGUUUGUGCCAG) and 
REV3L siRNA #2 (5'-AGACUGAGUGAGUCACCUG) (IDT). Cells were 
plated at a density of 0.5 x 106 per 60 mm dish 1 day before transfection. 
siRNA was transfected into the cells using Lipofectamine RNAiMAX 
(Invitrogen) at a final concentration of 0.01 μM for 72 h, according to the 
manufacturer’s instructions.  
 
2.3.9 Cell cycle analysis 
Cells were transfected with control siRNA or REV3L siRNA, and 
treated with or without dacomitinib for the indicated times. Following the 
treatment period, cell cycle distribution was determined using standard ethanol 
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fixation and propidium iodide staining followed by flow cytometry.  
2.3.10 Clonogenic survival assay 
Cells were transfected with either control siRNA or REV3L siRNA. 
Twenty four hours after transfection, cells were subjected to the treatment with 
either DMSO or the indicated dose of dacomitinib, paclitaxel or cisplatin for 
14 days. Colonies were stained with crystal violet 0.005%.  
 
2.3.11 Immunofluorescence 
Cells were transfected with control siRNA or REV3L siRNA, and 
treated with DMSO or 1 μM dacomitinib for 72 h. Following the treatment 
period, cell were fixed with 4% paraformaldehyde and permeabilized with 
ethanol. Primary antibodies include 200μg/μl mouse anti-phospho-γ-H2AX 
antibody (Upstate), or 1:100 mouse anti-BRCA1 (Ab-1) (Calbiochem) after 
blocking with goat serum. Secondary antibodies include 1:1000 anti-mouse 
Alexa488 conjugated antibody (Molecular Probe) or 1:1000 anti-Rabbit 
Alexa594 conjugated antibody (Molecular Probe). Staining patterns were 
visualized via fluorescence microscopy (Olympus). A total of 20 cells were 
counted per field, and a total of 10 fields were assessed. For foci analysis, cells 
with >10 γH2AX foci were counted. For BRCA1 localization, cells were 
assessed as having nuclear staining only, cytoplasmic staining only, or both 




Chapter 3 SETD2 histone modifier loss in aggressive GI stromal tumor 
Note: The findings in this chapter were published as (Huang, McPherson et al. 
2015). SETD2 immunohistochemistry was performed by Dr Kakoli Das, 
RNAseq analysis was performed by Dr Tannistha Nandi while transfection 
and drug treatment assays were performed by Dr Chia Na Yu and Longyu Hu. 
These works were necessarily included to aid logical flow of the writing and 
enable a more complete understanding of the research. 
 
3.1 GIST exome sequencing 
 We performed exome capture and Illumina next generation sequencing 
(NGS) on genomic DNAs from 18 GISTs and matched-normal blood samples 
from 14 GIST patients (Table 3.1). The GIST samples were imatinib-naïve 
surgically resected specimens. Of the 14 GIST patients, 9 were metastatic or 
classified as high-risk and 5 were classified as low- or intermediate-risk by 
Joensuu’s modified consensus criteria (Joensuu 2008). For three patients 
(HR1, HR5, HR8), we sequenced exomes of two separate metastases from the 
same individual excised at different time points, and for another patient 
(HR4), the exomes of both the primary and secondary tumors were analysed. 
The mean depth of sequence coverage was 81.2X for aligned reads. On 
average, 93% of targeted bases were covered at least ten times (Table 3.2). To 
identify somatic mutations, we performed Genome Analyzer Toolkit (GATK) 
variant calling with custom filtering, followed by manual inspection of the 
sequencing reads for each identified somatic variant.  
36 
 
We identified 261 exonic or splice-site somatic mutations within 
protein-coding genes across the 14 patients. We confirmed the NGS-identified 
somatic mutations by Sanger sequencing. Of 255 candidate mutations, 221 
were confirmed to be somatic mutations. The other 34 variants could not be 
tested due to PCR failure; hence the overall accuracy of our somatic detection 
pipeline is at least 87.6%. The final list of somatic mutations included 157 
missense, 56 loss of heterozygosity variants (variants heterozygous in blood 
but homozygous in tumor), 19 deletion, 13 nonsense, 9 splice-site and 7 
insertion mutations. On average, we identified 25.2 mutations per high-risk 
















3.2 Recurrently Mutated Genes in High- and Low-Risk GIST 
 We identified five genes to be recurrently mutated in more than one 
patient (Table 3.1; Supplementary table 4). These genes were KIT (14/14), 
SETD2 (3/14), TP53 (2/14), TRIOBP (2/14) and CSGALNACT1 (2/14). Of 
these, KIT and TP53 have previously established roles in GIST. Supporting 
the well-known role of KIT as a GIST driver mutation, we found KIT 
mutations in all 14 patients. Most of the KIT mutations occurred in exon 11, 
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with deletions predominating in high-risk GIST (8/9) and insertions or point 
mutations in low- and intermediate-risk GIST (4/5) (Fisher exact test, P=3x10
-
3
; Figure 3.1).  The other three recurrently-mutated genes (SETD2, TRIOBP 
and CSGALNACT1) have no previously reported role in GIST biology. 
Notably, SETD2 and TRIOBP mutations were found only in the high-risk 
patients, but not the low-/intermediate-risk cohort.  
 
Table 3.3. Recurrent mutations in GIST exomes by risk group 
 
PD = Probably damaging, B = benign, Ins = insertion, Del = deletion, FS = 
frameshift indels, NS = nonsense mutation, LOH = loss of heterozygousity, - = 




Figure 3.1: KIT mutations in exon 11 from exome of 14 GIST patients. Patient 







3.3 Heterogeneity of Mutational Profiles Between Multiple GISTs 
from the Same Patient 
 Four patients had exome sequence data from multiple distinct tumor 
specimens obtained at different time points. This information allowed us to 
compare intra-individual mutational profiles of different GISTs from the same 
patient. We observed varying degrees of heterogeneity, ranging from 41% 
(HR1) to 100% (HR4) of shared mutations between tumors in the same 
patient. Supporting the role of KIT as an early driver of GIST development, 
KIT mutations were always shared between multiple samples from the same 
patient. Notably however, mutations in two other key genes (TP53 and 
SETD2; see below) were often found in some, but not all, GISTs from the 
same patient, supporting the existence of heterogeneity (Figure 3.2). To rule 
out the possibility that this heterogeneity might be an artefact of insufficient 
sequence coverage, we performed ultra-deep amplicon sequencing (>2800x, 
see below) of SETD2 and confirmed that in patient HR8, SETD2 mutations 
(S815*) occurred in 38% of sequence reads from one metastatic lesion, but 
was completely absent in the other metastatic lesion. This data suggests that 
certain GISTs may continue to accumulate key driver mutations after 
diverging from the primary tumor, leading to metastatic tumors with different 
phenotypes. Indeed, TP53 mutations in GIST patients have been linked to 
higher risk of relapse (Ryu, Kang et al. 2007) and poorer response to tyrosine 





Figure 3.2: Tumour heterogeneity in GISTs. Venn diagrams showing total 
count of shared and private mutations in four patients with multiple tumour 
samples sequenced. Figures indicate number of mutations. Key shared and 
private mutated genes are listed. The site of origin of each tumour sample is 
indicated. P indicates primary tumours while M indicates metastases. 
 
3.4 SETD2 Mutations Associated with High-Risk GIST 
 Focusing on the five genes that had validated non-synonymous somatic 
mutations in more than one patient, we performed a mutational significance 
test using Genome MuSiC (Dees, Zhang et al. 2012). SETD2 was particularly 
notable among the list of recurrently mutated genes (P=9.5x10
-6
, FDR=0.09), 
ranking second in mutational significance behind KIT (Table 3.4). To extend 
these results beyond the exome-sequenced discovery series, we then 
performed targeted sequencing to validate the prevalence of KIT, PDGFRA 
and SETD2 mutations in an independent cohort of 125 GIST samples from 
120 unique patients that were either treatment naïve or treated with imatinib 
therapy. The mean coverage for amplicon sequencing was 2875X and on 
average 98.8% of target regions were covered at least 10 times. 
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Table 3.4: MuSiC significance of mutation from exome sequencing of 14 
GIST patients 
 
In the combined discovery and prevalence cohort of 134 unique GIST 
patients (Figure 3.3A), we identified 111 patients (82.8%) with activating KIT 
mutations and 10 patients (7.5%) with activating PDGFRA mutations. 
Mutations in KIT and PDGFRA were mutually exclusive while 13 patients 
(9.7%) were wild-type for both KIT and PDGFRA. The KIT mutations 
clustered within exon 9 (15 patients; 11.2%), exon 11 (94 patients; 70.1%), 
exon 13 (1 sample; 0.7%) and exon 17 (1 patients; 0.7%). Five of the KIT-
mutant samples harboured known secondary mutations in exon 13 (1 patient), 
exon 14 (1 patient) and exon 17 (3 patients) and occurred in patients treated 
with palliative imatinib. In exon 11, the most common form of mutations were 
deletions (64 patients; 47.8%), followed by point mutations (20 patients; 
14.9%) and insertions (10 patients; 7.5%). 
Most importantly, we found seven additional patients with SETD2 
mutations, beyond the original three in the discovery cohort. 50% of the 
mutations found in SETD2 were truncating mutations including frame shift 
indels and nonsense mutations, suggesting that they are loss-of-function 
mutations. Three of the SETD2 missense mutations affected highly conserved 
residues across different species (Figure 3.3B), and analysis using Polyphen2 
predicted that two of these three mutations are likely damaging to SETD2 
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function. In total, we identified SETD2 mutations in 10/89 (11.2%) of high-
risk or metastatic GISTs while no SETD2 mutations were observed from 34 
low- or intermediate-risk GISTs (Fisher exact test, two tailed P= 0.06). 
Notably, two patients exhibited GISTs carrying two independent mutations, 
consistent with biallelic inactivation and SETD2 playing a potential tumor 
suppressor role.  
 
Figure 3.3: SETD2 somatic mutations in high-risk GISTs. (A) Mutational 
landscape of KIT, PDGFRA and SETD2 in GIST. (B) SETD2 mutations in 
high-risk/ metastatic GIST. The location of SET domain is indicated. Bottom 
panel shows the conservation of missense mutation sites between different 
species. Conserved sites are indicated in red. Two-hit mutations occurring in 
the same patient are indicated by bordered circles. A197V and D324fs 
mutations are found in patient P81 while G1775R and Q2068* mutations are 




3.5 Functional Validation of SETD2 Mutations  
SETD2 is currently the only known histone modifying gene in the 
human genome that can catalyze H3K36 trimethylation (H3K36me3) 
(Edmunds, Mahadevan et al. 2008), a chromatin mark commonly associated 
with actively transcribed genes (Sims and Reinberg 2009). To assess the 
functional consequences of SETD2 mutation in GIST, we performed 
H3K36me3 immunohistochemistry analysis in both SETD2 wild-type and 
SETD2 mutant GISTs. SETD2 wild-type GISTs showed strong nuclear 
H3K36me3 expression in 80-90% of tumor cells, while SETD2 mutants 
showed weak nuclear expression in 70-80% of tumor cells (Figure 3.4A). This 
decrease in H3K36me3 expression supports the loss of SETD2 
methyltransferase activity in SETD2 mutant GISTs. 
We then proceeded to characterize the transcriptional consequences of 
SETD2 mutations in GIST by RNA sequencing (RNA-seq). A transcriptomic 
analysis of 8 high-risk gastric GIST samples (4 SETD2 mutant and 4 SETD2 
wild-type) revealed a distinct gene expression signature associated with 
SETD2 mutant GISTs, involving the upregulation of several genes within the 
HOXC cluster such as the HOTAIR lincRNA (Figure 3.4B). Previous studies 
have shown the association of these HOXC-related genes with high-risk grade, 
metastasis, and poor prognosis in GIST patients (Niinuma, Suzuki et al. 2012).  
In clear cell renal cell carcinoma (ccRCC), SETD2 loss has been 
associated with decreased DNA repair and increased DNA damage (Kanu, 
Gronroos et al. 2015). To further demonstrate the functional relevance of 
SETD2 loss to GIST tumorigenesis, we performed in vitro functional 
experiments where the relationship between SETD2 loss and DNA damage 
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was assessed by measuring levels of γ-H2Ax (a DNA damage marker) in 
GIST-T1 cells (Taguchi, Sonobe et al. 2002). siRNA-mediated silencing of 
SETD2 (Figure 3.4C) dramatically increased γ-H2Ax levels, particularly after 
sunitinib treatment, relative to control-treated cells (Figure 3.4D). Repeating 
this experiment using two independent SETD2 siRNAs also demonstrated an 
upregulation of γ-H2Ax upon SETD2 knockdown and treatment with sunitinib 
(Figure 3.3E). Taken together, these results strongly support a functional role 
for SETD2 mutations in GIST. 
 
 
Figure 3.4: SETD2 functional characterisation in GISTs. (A) Reduced 
H3K36me3 expression in two SETD2 mutant GISTs compared to two SETD2 
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wildtype GIST by immunohistochemistry (scale bar: 50 mm). (B) 
Differentially expressed genes associated with SETD2 mutations from 
RNAseq data. (C) SETD2 mRNA expression was efficiently depleted after 
siRNA mediated knockdown. (D) Upregulation of phosphorylated γ-H2Ax 
after SETD2 depletion (siSETD2) is enhanced by drug (sunitinib) treatment. 
(E) Upregulation of phosphorylated γ-H2Ax when SETD2 is depleted using 
two independent SETD2 siRNAs (siSETD2 #5 and #8) after sunitinib 
treatment as compared with sunitinib-treated negative control siRNA (siNT). 
β-actin serves as loading control. 
 
3.6 SETD2 Mutations are Associated with DNA Hypomethylation in 
Gastric GIST 
Several studies have suggested that H3K36me3 co-occurs with DNA 
hypermethylation (Ball, Li et al. 2009, Hawkins, Hon et al. 2010), likely due 
to the recruitment of DNA methyltransferases (e.g. DNMT3A or DNMT3B) to 
H3K36me3-occupied sites (Dhayalan, Rajavelu et al. 2010, Baubec, Colombo 
et al. 2015). In renal cell carcinoma (Cancer Genome Atlas Research 2013) 
and glioblastoma (Fontebasso, Schwartzentruber et al. 2013), SETD2 mutated 
tumors have been reported to exhibit distinct DNA methylation patterns 
compared to SETD2 wild-type samples. However, no study to date has 
analyzed which specific genomic regions (e.g. enhancers, transcribed regions, 
etc.) are epigenetically altered in SETD2 mutated tumors, and whether DNA 
methylation alterations associated with SETD2 mutations are similar or 
different between distinct tumor types.  
To evaluate the epigenetic consequences of SETD2 mutations in GIST, 
we performed DNA methylation analysis on 22 GIST samples (10 SETD2 
mutant and 12 SETD2 wild-type) using Illumina 450K methylation arrays. An 
unsupervised principal component analysis of the methylation data revealed 
the presence of three distinct epigenetic subgroups highlighting three major 
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points (Figure 3.5A). First, regardless of their SETD2 status, GISTs arising 
from the stomach (gastric GISTs) segregated apart from GISTs from the 
intestine, indicating that GIST tissue of origin has a strong imprint on the 
epigenetic profile of this disease. Second, within the gastric GIST cluster, we 
distinguished two additional clusters - one predominated by 5/6 SETD2 
mutated samples, and the other cluster comprising 6/7 SETD2 wild-type 
gastric GISTs (Fisher test, P=0.03). This result is consistent with the 
hypothesis that in gastric GIST, SETD2 may represent a major epigenetic 
driver in this tumor type.  Third, in contrast to gastric GISTs, for tumors 
originating from intestines, SETD2 mutated GISTs overlapped with SETD2 
wild-type GISTs. This finding may suggest that SETD2 functions in a highly 
tissue-specific context, with different functions in different tumor types.  
We then performed detailed high-resolution epigenetic comparisons 
between a) GISTs from different organs, and b) SETD2 wild-type and mutated 
gastric GISTS. First, we compared the methylation landscape between gastric 
and intestinal GIST. We identified a significant number of significantly 
hypomethylated (n=2,143) and hypermethylated (n=322) probes in SETD2 
wild-type intestinal GISTs compared to SETD2 wild-type gastric GISTs 
cluster (Figure 3.5B, 3.5C), suggesting a distinct origin for GISTs arising from 





Figure 3.5: DNA methylation landscape in GISTs. (A) Principal component 
analysis (PCA) plot of the 450k methylation data from 22 GIST samples. (B) 
Volcano plot showing the relative distribution of hypomethylated and 
hypermethylated probes between SETD2 wild type intestinal GIST and SETD2 
wild type gastric GIST (cluster 2) (C) Heatmap of beta values generated using 
the top 1000 most variable sites between gastric and intestinal GISTs. 
 
We then focused our analysis on methylation differences between 
SETD2 wild-type and mutated gastric GISTs. We observed vastly more 
hypomethylated probes in the cluster associated with SETD2 mutations 
(n=3,312) than the cluster associated with wild-type SETD2 (n=16) (Figure 
3.6A, 3.6B). Globally, SETD2 mutant gastric GISTs are also significantly 
hypomethylated compared to SETD2 wild-type gastric GIST (mean beta value 
of 0.411 in mutant cluster vs 0.466 in wild-type cluster; t-test P=3.4x10
-4
). 
These results point to a highly specific DNA hypomethylation signature in 
SETD2-mutated gastric GIST. In contrast, no probes were found to be 
significantly hypo- or hyper-methylated between SETD2 wild-type and 
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mutated GISTs originating from the intestine, possibly due to the small sample 
size.  
 
3.7 DNA Hypomethylation Events in SETD2-mutated Gastric GISTs 
are Associated with Heterochromatin 
In accordance with the reported link between H3K36me3 and de novo 
DNA methylation, we initially predicted that hypomethylated probes 
associated with SETD2 mutants should be concentrated at H3K36me3-rich 
actively-transcribed gene bodies. To explore this possibility, we correlated the 
genomic regions affected by SETD2-associated hypomethylation in gastric 
GIST with previous genome-wide chromatin state annotations from a closely 
related mesenchymal cell line (HSMM; human skeletal muscle myoblast), 
examining promoters, enhancers, transcribed regions and heterochromatin 
(Ernst, Kheradpour et al. 2011). Surprisingly, instead of transcribed regions, 
we found that hypomethylated regions in SETD2 mutant GISTs were highly 
enriched in chromatin states associated with transcriptionally silent 
heterochromatin and repetitive DNA satellites, relative to the overall 
background chromatin state of the 450k probes in the same cell line (76.1% vs 
24.1%; Binomial test, P<2.2x10
-16
; Figure 3.6C). Repeating this analysis using 
other ENCODE cell lines revealed a consistent enrichment of heterochromatin 
hypomethylation (Table 3.5), indicating that these results are robust and cell-
line independent. This analysis suggests hypomethylated heterochromatin may 
represent a characteristic epigenomic “signature” of SETD2 deficiency in 
gastric GIST.  
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 To validate the existence of a hypomethylated heterochromatin 
signature in GIST, we repeated the methylation analysis on a previously 
published GIST 450K methylation dataset (Killian, Kim et al. 2013). This 
validation dataset included SDH deficient GIST (n=25), KIT mutant GIST 
(n=44) and benign gastrointestinal muscle tissue (n=7). Our analysis 
confirmed the existence of two distinct subgroups (clusters 3 (n=31) and 4 
(n=11)) within KIT mutant GIST, characterized by divergent DNA 
methylation levels (mean beta value of 0.436 in cluster 3 vs 0.387 in cluster 4; 
t-test P=3.7x10-
4
) (Figure 3.6D). Relative to cluster 3, cluster 4 exhibited a 
similar hypomethylated heterochromatin signature as the SETD2 associated 
subgroup in our dataset (average beta difference < -0.1, FDR < 0.001; Figure 
3.6E), and there was a strong overlap between the hypomethylated 
heterochromatic locations in both analysis (Fisher test, P<2.2e-16, odds ratio= 
5.8). While SETD2 mutational status was not assessed in this validation 
dataset, our analysis suggests that SETD2-associated hypomethylated 




Figure 3.6: Heterochromatin hypomethylation in gastric GISTs. (A) Volcano 
plot showing the relative distribution of hypomethylated and hypermethylated 
probes between SETD2 mutant associated gastric cluster (clusters 1) and 
SETD2 wild type associated gastric GIST (cluster 2) (B) Heatmap of the top 
1000 most variable sites between Cluster 1 and Cluster 2. (C) Density plot of 
average methylation level between SETD2–mutant associated cluster 1 and 
SETD2 wild type associated cluster 2 in heterochromatic and non-
heterochromatic sites. (D) PCA plot of the 450k methylation data from the 
validation data set. (E) Volcano plot showing the relative distribution of 
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hypomethylated and hypermethylated probes between cluster 3 and cluster 4 
in the validation data set. 
 
Table 3.5: Chromatin states enrichment of hypomethylated probes in SETD2 
mutant gastric GIST 
 
GM12878 (B-lymphoblastoid cell), H1 ES (embryonic stem cell), HepG2 
(hepatocellular carcinoma cell), HMEC (mammary epithelial cell), HSMM 
(skeletal muscle myoblast), HUVEC (umbilical vein endothelial cell), K562 
(erythrocytic leukaemia cell), NHEK (normal epidermal keratinocyte) and 
NHLF (normal lung fibroblast). 
 
3.8 SETD2 Mutants Show Different Epigenomic Landscapes in 
Distinct Tumor Types 
To ask if the SETD2-associated hypomethylated heterochromatin 
signature observed in gastric GIST might be observed in other tumors types, 
we then examined published 450K methylation profile of clear cell renal cell 
carcinoma (RCC) (https://tcga-data.nci.nih.gov) and pediatric high-grade 
glioblastoma (GBM) (Fontebasso, Papillon-Cavanagh et al. 2014), two tumor 
types with high SETD2 mutation frequencies. In RCC, 41% (440/1064) of 
differentially methylated loci between SETD2 mutant and wild-type tumors 
were hypomethylated (average beta difference < -0.1, FDR < 0.001) in SETD2 
mutant samples, with strong enrichment at highly transcribed chromatin states 
associated with euchromatic H3K36me3 (53% of hypomethylated probes 
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versus 7% in the background) (Table 3.6). In GBM, we identified a total of 
224 probes differentially methylated between SETD2 mutant (excluding 
SETD2 mutant with concomitant IDH1 mutation) compared to 
SETD2/IDH1/H3F3A wild-type samples. Of these, 35 probes (15.6%) were 
hypomethylated (average beta difference < -0.1, FDR < 0.05) and the 
hypomethylated sites were enriched at CTCF-marked insulator regions (Table 
3.7). These analyses suggest that while aberrant DNA methylation may be a 
common consequence of SETD2 mutations, the specific genomic regions 
affected by the methylation aberrations may be tissue-type dependent.  
 
Table 3.6: Chromatin states enrichment of hypomethylated probes in SETD2 
mutant RCC 
 
GM12878 (B-lymphoblastoid cell), H1 ES (embryonic stem cell), HepG2 
(hepatocellular carcinoma cell), HMEC (mammary epithelial cell), HSMM 
(skeletal muscle myoblast), HUVEC (umbilical vein endothelial cell), K562 
(erythrocytic leukaemia cell), NHEK (normal epidermal keratinocyte) and 





Table 3.7: Chromatin states enrichment of hypomethylated probes in SETD2 
mutant GBM 
 
GM12878 (B-lymphoblastoid cell), H1 ES (embryonic stem cell), HepG2 
(hepatocellular carcinoma cell), HMEC (mammary epithelial cell), HSMM 
(skeletal muscle myoblast), HUVEC (umbilical vein endothelial cell), K562 
(erythrocytic leukaemia cell), NHEK (normal epidermal keratinocyte) and 
NHLF (normal lung fibroblast). 
 
3.9 SETD2 Loss Predicts Short Relapse Free Survival in GIST 
 To assess the clinical impact of KIT/PDGFRA and SETD2 mutations in 
GIST, we then correlated the different driver mutations to clinic-pathologic 
characteristics (primary tumor size, mitotic rate, and tumor site) and relapse-
free survival (Table 3.8). Since our entire series was heterogenous, consisting 
of treated and untreated, primary and metastatic samples, to estimate the 
relative risk of recurrence without intervention of adjuvant treatment, we 
excluded from analysis all patients that received treatment or were metastatic 
at the time the samples were obtained. Using this filter, a total of 68 untreated 
primary samples with complete clinical information were thus analysed.  
55 
 
Table 3.8: Univariable and multivariable Cox regression analysis for relapse-




In univariate analysis, large tumor size (P=3.1x10
-4
) and high mitotic 
rate (P=3.4x10
-6
) were associated with increased risk for tumor recurrence 
(Figure 3.7A, 3.7B). We observed a significant difference in relapse-free 
survival between patients with different KIT/PDGFRA genotypes (P=0.01), 
with KIT exon 11 deletion mutants (P=3.9x10
-3
) and KIT exon 9 mutants 
(P=0.04) trending towards higher risk for tumor recurrence compared to 
tumors with mutations other than KIT exon 11 deletions/exon 9 mutations 
(Figure 3.7C). Significant differences in recurrence-free survival between 
PDGFRA-mutant (P=0.42) and wild-type KIT/PDGFRA (P=1) samples with 
other types of KIT mutants were not observed. Samples with SETD2 mutations 
or hypomethylated heterochromatin was also significantly associated with 
high risk of relapse (P=2.3x10
-3
; Figure 3.7D). When subjected to multivariate 
analysis, only mitotic rate was a predictor of relapse-free survival (P=3.1x10
-
6
), while SETD2 inactivation (P=0.21) and KIT/PDGFRA (P=0.13) genotype 
were not independently associated.  
We also performed the survival analysis, stratified by the primary 
tumor site (51 gastric GISTs and 17 intestinal GISTs). Tumor mitotic rate 
remained the single most important prognostic factor in gastric GIST (Table 
3.9) while tumor size appeared to be more dominant in intestinal GISTs (Table 
3.10). Notably, despite the small number of samples, tumors with SETD2 
mutation or hypomethylated heterochromatin were significantly associated 
with high risk of recurrence in gastric GISTs (P=4.1x10
-5
; Figure 3.6E) but 
not in intestinal GISTs (P=0.60; Figure 3.7E). In multivariate test, SETD2 
mutations did not reach statistical significance (P=0.08), although this 
observation will need to be re-evaluated in a larger dataset. These results 
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suggest that SETD2 mutations, or the presence of hypomethylated 





Figure 3.7: Association between relapse-free survival and risk factors. 
Associations between relapse-free survival with (A) tumour size, (B) mitotic 
rate, (C) KIT/PDGFRA mutation types, (D) SETD2 mutational status, (E) 
SETD2 mutational status or SETD2-associated methylation pattern in gastric 
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GI stromal tumours (GISTs) and (F) SETD2 mutational status in intestinal 
GISTs. Number of persons at risk at several time points is indicated. 
 
Table 3.9 Univariable and multivariable Cox regression analysis for relapse-





Table 3.10 Univariable and multivariable Cox regression analysis for relapse-
free survival after primary resection in intestinal GISTs 
 
 
3.10 SETD2 Inactivated Tumors May Benefit from Adjuvant Imatinib 
Treatment 
 Finally, in an exploratory study, we assessed the impact of adjuvant 
imatinib on relapse-free survival of the GIST patients in our cohort. Due to the 
retrospective nature of this study, decisions regarding adjuvant therapy for 
these patients were based on existing evidence-based knowledge at the point 
of diagnosis, patient’s general health status, and clinical assessment of risk 
factors for relapse. Given these caveats and small sample size examined, in the 
overall cohort of treated high risk patients (n=17) compared to untreated high 
risk patients (n=36), we did not observe a significant improvement in relapse-
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free survival (Figure 3.8A; P=0.12). However, relapse-free survival of 
adjuvant-treated patients with KIT exon-11 deletion mutation were 
significantly longer than untreated patients with the same genotype (Figure 
3.8B; P=6.8x10
-3
). We observed a trend toward imatinib benefit in adjuvant-
treated samples with SETD2 mutations or hypomethylated heterochromatin 
compared to untreated SETD2-mutant samples (Figure 3.8G; P=0.12). When 
only gastric GISTs were considered, we observed a significant benefit of 
imatinib in SETD2 mutant patients (Figure 3.8H; P=0.04), suggesting 
molecular information may potentially be utilized as predictive biomarker to 
facilitate GIST patient stratification. 
 
Figure 3.8: Impact of adjuvant imatinib on patient with genotype (A) overall 
unstratified population (B) KIT exon 11 deletion, (C) KIT exon 9 mutation, 
(D) KIT mutation other than (B) and (C), (E) wildtype KIT/PDGFRA (F) 
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PDGFRA mutation, (G) SETD2 mutation or methylation and (H) SETD2 
mutation or methylation in gastric GIST 
 
3.11 Discussion 
 In this study, we performed exome sequencing on a cohort of low- and 
high-risk GISTs to better understand the landscape of genetic mutations 
associated with this disease. For the majority of GISTs, the initiating mutation 
is believed to involve activation of either the KIT or PDGFRA proto-
oncogenes. Our findings support this, where almost all GISTs sequenced 
(including multiple samples from the same patient) harboured either KIT or 
PDGFRA activating mutations. The KIT and PDGFRA mutations found in this 
study clustered at known hotspot mutational sites, consistent with these 
mutations causing oncogene activation. However, although the importance of 
KIT/PDGFRA mutations to early GIST development is undeniable, it is also 
unlikely that mutations in KIT/PDGFRA alone can account for the wide 
spectrum of GIST malignancy potential because KIT alterations are found in 
all GIST subtypes including a subtype of non-malignant GIST with sizes less 
than 1 cm(Corless, McGreevey et al. 2002, Agaimy, Wunsch et al. 2007). As 
such, additional genetic alterations are likely present in GIST, which further 
contribute to the clinical heterogeneity observed in this condition.  
GIST somatic mutations in several other genes have been reported, 
although none of them account for more than 2% of all GISTs(Corless, 
Barnett et al. 2011). BRAF V600E mutations have been reported in between 3 
to 13% of wild-type GIST and this subgroup of patients may benefit from 
treatment with BRAF inhibitors(Falchook, Trent et al. 2013). Germline or 
somatic inactivation via mutations and promoter hypermethylation of the 
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succinate dehydrogenase subunits (SDHA, SDHB, SDHC, SDHD) has been 
observed in subsets of pediatric GIST characterized by overexpression of 
IGF1R(Nannini, Astolfi et al. 2013, Killian, Miettinen et al. 2014). In addition 
to the mutually exclusive KIT/PDGFRA/BRAF/SDH mutations, rare cases of 
activating mutations at hotspot codons of KRAS and PIK3CA have also been 
reported. In this study, we observed a PIK3CA H1047R mutation in both 
primary and secondary tumor of patient HR4. The presence of a canonical 
activating PIK3CA mutation may explain the aggressive behaviour of GIST in 
this patient.  
 Our study identified several genetic differences between low- and 
high-risk GISTs. High-risk GISTs were associated with an increased number 
of somatic mutations, and the precise type of KIT mutations also seemed to 
contribute to GIST progression. Specifically and consistent with previous 
reports (Lasota, Dansonka-Mieszkowska et al. 2003, Andersson, Bumming et 
al. 2006), GISTs with deletions involving KIT exon 11 and possibly mutations 
in KIT exon 9 appeared to be associated with a higher risk profile than other 
types of KIT mutations. We did not observe a statistical difference between 
PDGFRA mutant and KIT/PDGFRA wild-type GISTs with respect to risk of 
recurrence. 
Our study suggests that SETD2 may represent a novel GIST tumor 
suppressor gene, which contributes to GIST progression. Several lines of 
evidence support this conclusion. First, SETD2 mutations were only found in 
high-risk but not low-risk GIST. Second, SETD2 deletions were distributed 
throughout the entire gene and most were either frame-altering indels or 
nonsense mutations, a typical pattern of tumor-suppressor mutations. In two of 
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the samples with SETD2 mutations, we observed two separate mutational 
events in each case, indicating biallelic inactivation consistent with a tumor 
suppressor function. Third, in one patient where two metastases were profiled, 
we identified and validated the presence of SETD2 mutation in one metastases 
but not the other, suggesting that SETD2 mutations occur at a later stage of 
tumorigenesis. Thus, in our dataset, SETD2 mutations appear to be associated 
with GIST progression, rather than initiation. It is possible that the subclonal 
nature of the SETD2 mutations may have limited our sensitivity to identify 
additional cases within our series exhibiting SETD2 loss-of-heterozygozity by 
copy number analysis or promoter hypermethylation.   
SETD2 encodes a histone modifying gene whose protein is responsible 
for H3K36 trimethylation (H3K36me3) in humans (Edmunds, Mahadevan et 
al. 2008). SETD2 binds to elongating RNA polymerase II, leading to 
deposition of H3K36me3 at bodies of actively transcribed genes. The 
methylated H3K36 subsequently recruits the FACT (Facilitates Chromatin 
Transcription) complex which functions to maintain chromatin integrity 
during gene transcription (Carvalho, Raposo et al. 2013). SETD2 has also 
recently been shown to have a role in DNA mismatch repair mechanism by 
recruiting MSH6 to chromatin (Li, Mao et al. 2013). Tumor cell lines depleted 
of SETD2 display losses of H3K36me3 chromatin marks, fail to recruit MSH6 
to chromatin and are characterized by increased rates of spontaneous 
mutations (Li, Mao et al. 2013). These studies provide further support that 
SETD2 inactivation could lead to tumorigenic growth advantages in GIST, via 




 SETD2 somatic mutations had also been previously described in 
ccRCCs (Dalgliesh, Furge et al. 2010, Varela, Tarpey et al. 2011) and 
glioblastomas (Fontebasso, Schwartzentruber et al. 2013). Importantly, data 
from both cancer types supports our own data that SETD2 may function as a 
driver of tumor progression. In multi-region ccRCC exome sequencing, 
multiple independent SETD2 mutations were found to occur at later stages of 
ccRCC clonal evolution (Gerlinger, Rowan et al. 2012). SETD2 mutations 
were also found to co-occur with PBRM1 and VHL mutations (Pena-Llopis, 
Christie et al. 2013) and correspond to poor cancer-specific survival and 
higher likelihood of developing metastatic diseases in ccRCC (Hakimi, 
Ostrovnaya et al. 2013). Similarly, SETD2 mutations are found in hemispheric 
high-grade gliomas but not low-grade gliomas (Fontebasso, Schwartzentruber 
et al. 2013). In breast cancer, SETD2 expression correlates with progression of 
disease with tumors from metastatic patients showing significantly lower 
SETD2 transcript levels compared to patients that are relapse-free (Al Sarakbi, 
Sasi et al. 2009). 
Interestingly, despite the common association of SETD2 mutations 
with disease progression in multiple tumor types, our data suggests that 
SETD2 mutations may cause epigenomic aberrations in a highly tissue-
specific manner, at least at the DNA methylation level. It is of relevance to 
examine DNA methylation changes in SETD2-mutated cancers, as several 
studies have shown that H3K36me3 co-occurs with DNA hypermethylation 
(Ball, Li et al. 2009, Hawkins, Hon et al. 2010), due to recruitment of 
DNMT3A/B to H3K36me3-occupied sites (Dhayalan, Rajavelu et al. 2010, 
Baubec, Colombo et al. 2015). In gastric GISTs, SETD2-mutations were 
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associated with hypomethylated heterochromatin which is believed to be 
transcriptionally silent, while SETD2-mutated ccRCCs exhibited 
hypomethylation at actively transcribed, euchromatic gene bodies. We further 
confirmed that a characteristic signature of hypomethylated heterochromatin 
could be observed in an independent cohort of GISTs. Heterochromatins are 
highly condensed, transcriptionally silent chromatin structure maintained by 
high level of DNA methylation. One possible explanation for the 
heterochromatin association in GIST is that while H3K36me3 is generally 
associated with active transcription, emerging data indicates that certain 
heterochromatic regions are also enriched in H3K36me3 deposited in a 
transcription-independent pathway (Chantalat, Depaux et al. 2011, Hahn, Wu 
et al. 2011). We propose that SETD2 mutations in gastric GIST may result in a 
failure to recruit DNA methyltransferases to heterochromatin, consequentially 
resulting in the removal of repressive DNA methylation marks at the same 
sites. Further studies to elucidate the localization of H3K36me3 marks in 
different cell types may be required to understand the different phenotypes 
associated with SETD2 mutations. 
 From a clinical perspective, our results suggest that KIT activation 
through KIT exon 11 deletions (and potentially exon 9) and SETD2 
inactivating mutations are potential markers for poor prognosis. In this regard, 
although several small molecule inhibitors targeting KIT are available, no 
therapeutic strategies that reactivate SETD2 function currently exist. Further 
studies are required to assess the feasibility of restoring SETD2 function as a 
therapeutic strategy in GIST. Notably, our small sample of treated and 
untreated SETD2 mutated patients indicates that Imatinib, a common 
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therapeutic option in GIST, could still be effective for these patients in the 
adjuvant setting, although a dedicated study to evaluate this observation is 
required. 
 In summary, using next generation sequencing platform, we provide 
for the first time, a detailed comparison of somatic alterations between high- 
and low-risk GISTs in an attempt to interrogate genetic markers responsible 
for disease phenotype. Although we focused on KIT, PDGFRA and SETD2, 
our analysis also identified two other recurrently mutated genes, 
CSGALNACT1 and TRIOBP as well as an activating PIK3CA mutation may 
also be involved in GIST tumorigenesis. The discovery of a role for the loss of 
SETD2 in GIST progression and its association with aggressive disease may 
have clinical utility in the refinement of current risk stratification strategies 






Chapter 4 Exome sequencing reveals recurrent REV3L mutations in 
cisplatin-resistant squamous cell carcinoma of head and neck 
Note: The findings in this chapter were published as (Huang, Jang et al. 2016). 
All wet-lab procedures described in this chapter were performed by Dr Kang 
Won Jang and were necessarily included to aid logical flow of the writing and 
enable a more complete understanding of the research. 
 
4.1 Patient characteristics and study design 
Of 48 patients enrolled in a phase II trial exploring the efficacy of 
dacomitinib in recurrent SCCHN, 18 patients had received cisplatin-based 
chemotherapy and were eligible for rebiopsy (Figure 4.1). The tumor 
characteristics and the response to dacomitinib were described (Table 4.1 and 
Table 4.2).  
 
Figure 4.1: Study design and classification of dacomitinib-sensitive and –
resistant patients. SCCHN patients were enrolled into a phase II clinical trial 
exploring the efficacy of dacomitinib in recurrent SCCHN 
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Table 4.1 Clinicopathologic features of SCCHN patients (n=18) 
Characteristic No. of Patients % 
Sex 
  
Male 15 83.3 
Female 3 16.7 
Age, years 
  
Median (Range) 61 (40-78) 
Performance status 
  
0 1 5.6 
1 15 83.3 
2 2 11.1 
Smoking history 
  
Never smoker 5 27.8 
Smoker, pack-years 
  
  ≤ 10 1 5.6 
  > 10 12 66.6 
Primary site 
  
Oral cavity 8 44.4 
Oropharynx 4 22.3 
Hypopharynx 2 11.1 
Larynx 2 11.1 
Maxillary sinus 2 11.1 
Disease status at study entry 
  
Locoregional 9 50.0 
Distant 1 5.6 
Both 8 44.4 
Number of involved disease sites 
  
1 2 11.1 
2 4 22.3 
≥3 12 66.6 
Prior treatment 
  
Cisplatin-based chemotherapy* 18 100 
Radiation 15 83.3 
Surgery 17 94.4 
P16 status
§
   
       Positive 4 22.2 
       Negative 11 61.2 
Unknown 3 16.6 
*Includes cisplatin alone, 5-fluorouracil plus cisplatin, docetaxel plus  
cisplatin, or docetaxel plus 5-fluorouracil plus cisplatin. 
§
The p16 












Tumor response*     
Complete response (CR) 0 0 
Partial response (PR) 1 5.6 
Stable disease (SD) 13 72.2 
Progressive disease (PD) 4 22.2 
Dacomitinib-sensitive** 7  38.9 
Dacomitinib-resistant*** 11     61.1 
*Response evaluations were defined according to RECIST 1.1 guidelines. 
Radiographic imaging was conducted at week 4, and every 8 weeks 
thereafter until disease progression or when clinically indicated.  
**Defined as progression-free survival ≥4 months on dacomitinib.  
***Defined as progression-free survival <4 months on dacomitinib. 
 
Based on response to dacomitinib, we classified tumors into 
dacomitinib-sensitive (n = 7) or dacomitinib-resistant (n = 11) tumors. 
Dacomitinib-sensitive tumors were defined as progression-free survival (PFS) 
≥4 months on dacomitinib according to Response Evaluation Criteria in Solid 
Tumors (RECIST 1.1), because most salvage therapies with either cytotoxics 
or EGFR inhibitors in platinum-resistant SCCHN have shown PFS of 
approximately 2 months(Soulieres, Senzer et al. 2004, Colevas 2006, 
Vermorken, Trigo et al. 2007, Stewart, Cohen et al. 2009, Machiels, 






4.2 Mutational landscape of recurrent SCCHN tumors 
The WES results from germline and tumor pairs were summarized 
(Table 4.3). Tumor-germline pairs were sequenced to a mean coverage of 
153X and 91X. Overall, we identified 10,115 somatic coding single nucleotide 
variants (SNVs) and small insertions/deletions (indels). Mutation rates were 
































































































































































*The tumor and matched normal genomes are discriminated with the use of 
'T' and 'N', respectively. 
**The mean and median coverage as well as the % of bases (>= 20 reads) 
were calculated onto the targeted regions (Agilent SureSelect 50Mb exon).  
 
Compared with the 279 SCCHN mutation profiles from chemotherapy-
naïve SCCHN of The Cancer Genome Atlas consortium (TCGA),(Cancer 
Genome Atlas 2015) the 18 SCCHN cisplatin-treated samples exhibited 
significantly higher mutation rates (median 13.7 vs 4.4 mutations/Mb; 
Wilcoxon test, P=6.8x10
-8
). The mutation rate in our cohort of cisplatin-
treated SCCHN is comparable to or higher than the mutation rates observed in 
melanoma (median 13.2 mutations/Mb), lung squamous cell carcinoma 
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(median 8.2 mutation/Mb) and lung adenocarcinoma (median 6.4 
mutation/Mb), the cancer types associated with chronic exposure to mutagenic 
agents (Fig. 4.2) (Lawrence, Stojanov et al. 2013).  
We observe a variable Ti/Tv (transition-vs-transversion) ratios across 
the genomes (range 0.19 - 3.93; median 0.76), indicating distinct mutational 
processes in different patients (Fig. 4.2). The relatively low Ti/Tv ratios of the 
18 SCCHN genomes are largely attributed to the overrepresentation of C>A 
transversions in some patients. Most predicted somatic mutations in our cohort 
have low variant allele frequency, despite tumor purity estimate of more than 
70%. The majority (76.1%) of the predicted SNVs are found in less than 20% 
of all the tumor sequencing reads, including most (91.9%) of the cisplatin-





Figure 4.2 Mutational landscape of cisplatin-resistant SCCHN. (A) Mutation 
rate in cisplatin-resistant SCCHN compared to mutation rate in other major 
tumor types. Each dot represents the mutation rate in a single tumor. The 
median mutation rate is indicated by red bar (B) Relative proportion of the six 
mutational spectra as indicated in the legend box in each tumor sample. (C) 
Variant allele frequency in SCCHN. Each dot represents the variant allele 
frequency of a predicted mutation. Colors indicate the mutational spectra as 
indicated by legend box in Fig. 2B. Design and data for Fig. 4.2A, 4.2B are 




4.3 Mutational signature in recurrent SCCHN 
We extracted five distinct mutational signatures representing unique 
mutational processes operative in SCCHN genomes (Fig. 4.3A and Figure 
4.4).  In addition to the four signatures that have been previously reported to 
be associated with SCCHN (Alexandrov, Nik-Zainal et al. 2013) (i.e., 
APOBEC, age, ultraviolet, and smoking corresponding to signatures 2 – 5; 
Fig. 4.3B), we identified a mutational signature that has not been previously 
reported in a large-scale analysis across 30 tumor types (signature 1; Fig. 
4.3B) (Alexandrov, Nik-Zainal et al. 2013). This signature is characterized by 
the prominence of C>A mutations mainly occurring on CpCpA and CpCpG 





Figure 4.3: Mutational signatures in R/M SCCHN. (A) Relative frequencies 
of 96 trinucleotides are shown for cisplatin-treated and cisplatin-naïve 
SCCHN above and below, respectively. (B) The deciphered five mutational 
signatures are shown for their relative frequencies across 96 trinucleotides. 
Note that signature 1 (platinum) contributes to a substantial level of 




Figure 4.4: The results of stability test and the contribution of the five 
predicted mutational signatures to individuals SCCHN genome (A) The 
optimal number of mutational signatures can be determined by permutation 
tests. The plot shows that increasing the number of mutation signatures to five 
does not substantially reduce the signature stability suggesting that five 
deciphered signatures are reproducible. (B) Each bar represents a SCCHN 
tumor sample. Vertical axis denotes the number of mutations per sample 
contributed by distinct mutational processes as indicated in the legend.  
 
The sequence composition of this novel signature is associated with the 
mechanistic action of cisplatin. Platinum preferably forms intrastrand 
crosslinks between purines with the Pt-GpG adducts being the most frequently 
formed DNA adducts (Kelland 2007). In addition, the substantial C>A 
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mutation on CpC dinucleotides, especially those preceding purines, suggested 
the preferential misincorporation of adenine opposite the 5’G of the Pt-GpG 
adducts. This preference for insertion of adenine across DNA lesion is 
reminiscent of the “A-rule” phenomenon observed in cells undergoing 
translesion DNA synthesis (TLS) (Strauss 2002). We therefore, proposed that 
the major substitution associated with cisplatin are TpGpG > TpTpG and 
CpGpG > CpTpG and this sequence preference may arise from activated 
error-prone translesion DNA replication activity on the DNA binding sites of 
cisplatin (Vaisman, Masutani et al. 2000). Thus, signature 1 in our dataset had 
been annotated as ‘platinum’. This mutational  signature was unlikely to be 
associated with prior exposure to radiation, because a significant fraction of 
DNA damage produced by ionizing radiation comes from free radicals 
generated during the radiolysis of water, leading to single-strand breaks of 
DNA (Teoule 1987). 
 
4.4 REV3L is recurrently mutated in dacomitinib-sensitive tumors  
To identify significantly mutated genes in recurrent SCCHN genomes, we 
performed the mutational significance test using the Genome MuSiC 
algorithm (Dees, Zhang et al. 2012). We include only variants with allele 
frequency of more than 20% in this analysis, reasoning that low frequency 
variants not subjected to stringent selection are likely to be passenger 
mutations from the diverse mutational processes or subclonal events.  
Using this approach and focusing on genes recurrently mutated in more 
than one patient, we identified 24 mutated genes showing trends towards 
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higher mutation rate compared to the background mutation rate (convolution 
test, FDR < 0.2; Table 4.4). This set of genes includes well known driver 
cancer genes including TP53, CDKN2A, FBXW7 and KRAS. Applying the 
same procedure on the dacomitinib-sensitive patients (n = 7; Table 4.5) and 
dacomitinib-resistant patients (n = 11; Table 4.6) identified another two genes 
(REV3L and EPYC) to be frequently mutated in dacomitinib-sensitive patient 
but not in the overall cohort. No genes were found to be significant in 
dacomitinib-resistant but insignificant in the overall cohort. Along with 
REV3L and EPYC, a total of 26 predicted significantly mutated genes are 





Table 4.4: Genome MuSiC significance test in the overall cohort (n=18) 
#Gene Indels SNVs P-value CT FDR CT 
TP53 0 10 0.0E+00 0.0E+00 
TMPRSS13 3 2 2.9E-10 2.6E-06 
C10orf113 3 0 1.0E-08 4.7E-05 
GLYR1 3 0 1.2E-06 4.2E-03 
ELAVL3 2 1 2.7E-06 8.3E-03 
DPY19L3 0 3 8.5E-06 1.7E-02 
CDKN2A 0 3 8.6E-06 1.7E-02 
RPS15 0 2 1.2E-05 2.2E-02 
ENTPD6 1 2 3.3E-05 5.2E-02 
TBP 2 0 4.2E-05 5.5E-02 
FBXW7 0 3 4.2E-05 5.5E-02 
HIST1H3H 0 2 6.3E-05 7.6E-02 
ARRDC5 1 1 8.5E-05 9.1E-02 
MAMSTR 2 0 9.4E-05 9.5E-02 
NOP58 2 0 1.2E-04 1.1E-01 
TM4SF18 0 2 1.2E-04 1.1E-01 
IRF5 2 0 1.6E-04 1.4E-01 
KRAS 0 2 1.8E-04 1.4E-01 
CRIPAK 0 2 1.7E-04 1.4E-01 
ZNF658 0 2 2.1E-04 1.5E-01 
CNTN6 0 3 2.2E-04 1.5E-01 
NR1H4 0 2 2.4E-04 1.5E-01 
DNMT1 2 1 2.7E-04 1.6E-01 





Table 4.5: Genome MuSiC significance test in the dacomitinib-responsive 
cohort (n=7) 
#Gene Indels SNVs P-value CT FDR CT 
TP53 0 4 3.2E-09 5.9E-05 
TBP 2 0 4.3E-06 3.9E-02 
EPYC 0 2 5.0E-05 1.2E-01 
REV3L 2 1 3.8E-05 1.2E-01 
CDKN2A 0 2 5.4E-05 1.2E-01 
HIST1H3H 0 1 4.3E-05 1.2E-01 
 
Table 4.6: Genome MuSiC significance test dacomitinib-resistant cohort 
(n=11) 
#Gene Indels SNVs P-value CT FDR CT 
TP53 0 6 4.5E+02 6.6E-14 
C10orf113 3 0 6.2E+02 3.0E-09 
TMPRSS13 2 2 2.1E+02 3.2E-08 
ARRDC5 1 1 1.8E+02 4.2E-05 
IRF5 2 0 1.2E+02 5.4E-05 
TM4SF18 0 2 2.9E+02 5.9E-05 
GLYR1 2 0 1.1E+02 7.2E-05 
CNTN6 0 3 8.6E+01 8.2E-05 
 
For the 26 somatic variants, only REV3L showed significant 
enrichment to dacomitinib-sensitive tumors (P = 0.04; Fisher’s exact test; 
Figure 4.5B). Most of identified REV3L mutations are apparently loss-of-
functional events (one missense mutation and two frameshifting indels; Figure 
4.5C), suggesting that the loss of functions in REV3L may confer sensitivity to 
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dacomitinib. All three REV3L variants were not present in dbSNP135, 
1000Genomes or the NIH-NHLBI6500 exome databases, indicating that these 
mutations may be pathogenic.  
We next compared the mutation frequency of TP53, CDKN2A, 
FBXW7, KRAS and REV3L in our cohort of cisplatin-resistant SCCHN against 
TCGA SCCHN exomes. We observed significant enrichment of mutations in 
REV3L (Fisher exact test, P = 0.02) and KRAS (Fisher exact test, P = 0.01) in 
our dataset compared to TCGA (Figure 4.5D). Notably, two cisplatin-resistant 
patients harboured the hotspot G12D KRAS mutation, an alteration that is 
rarely observed in treatment-naive SCCHN (Agrawal, Frederick et al. 2011, 
Stransky, Egloff et al. 2011, Cancer Genome Atlas 2015). Consistent with this, 
we observed an additional REV3L frameshift indel in one dacomitinib-
sensitive tumor (T15) at a very low frequency (<5%). Strongly supporting our 
hypothesis, all three REV3L mutations were confirmed in cisplatin-treated 
samples but not in cisplatin-naïve samples using bi-directional Sanger 
sequencing (Figure 4.6). The final REV3L mutations were predicted at below 




Figure 4.5: REV3L mutation in dacomitinib-sensitive SCCHN. (A) Recurrent 
mutations in metastatic SCCHN. All recurrently mutated genes that are 
significantly mutated in either dacomitinib-sensitive patients, dacomitinib-
resistant patients or the overall cohort are included in this figure. (B) 
Putative biomarkers for dacomitinib responsiveness. Figure showed the 
mutational significance (- log uncorrected P value from genome MuSiC’s 
convolution test) in dacomitinib-sensitive and dacomitinib-resistant patients. 
Gene with significant enrichment in dacomitinib-sensitive compared to 
dacomitinib-resistant cohort are indicated (Fisher exact test P < 0.05). (C) 
Mapping of somatic mutations in REV3L. The single patient with low 
frequency REV3L mutation is indicated with asterisk. (D) Mutational 
frequency of TP53, CDKN2A, FBXW7, KRAS and REV3L in cisplatin-
treated SCCHN (n = 18) and TCGA’s cisplatin-naïve SCCHN 
(n = 279). P value (Fisher exact test) between the mutation frequencies for 









4.5 REV3L inactivation confers sensitivity to dacomitinib 
Inactivation of REV3L induces accumulation of persistent DNA 
damages containing unrepairable DNA double strand breaks (DSBs) in cancer 
cells, leading to suppression of tumor cell growth and induction of cellular 
senescence (Knobel, Kotov et al. 2011).  EGFR inhibitors induce cell cycle 
arrest and cellular senescence in tumor cells sustaining DNA DSBs by 
suppressing DNA repair capacity (Chinnaiyan, Huang et al. 2005, Wang, 
Morsbach et al. 2011). Therefore, we hypothesize that there is a favourable 
antitumor interaction between REV3L inactivation and dacomitinib via 
accumulation of unrepairable DNA DSBs. 
We first measured the mRNA expression of REV3L in two 
dacomitinib-sensitive cells (CAL27, CAL33) and two dacomitinib-resistant 
cells (FADU, MSKQLL2). All four cell lines showed similar levels of REV3L 
mRNA expressions, regardless of their sensitivity to dacomitinib, suggesting 
that significant REV3L depletion may be required for meaningful functional 
effects on dacomitinib sensitivity (Figure 4.7). We selected two cell lines 
(FADU, MSKQLL2) with strong resistance to dacomitinib (IC50 > 1 μM) for 





Figure 4.7: mRNA expression of REV3L and cell viability to dacomitinib in 
head and neck cancer cell lines 
 
Next, we evaluated whether REV3L depletion may enhance sensitivity 
to dacomitinib in FADU and MSKQLL2 cells. Compared to dacomitinib or 
siREV3L alone, combined treatment of dacomitinib and siREV3L significantly 
induced G0/G1 arrest in both cells (Figure 4.8A). Consistent with the effects 
of siREV3L on cell cycle arrest, the antiproliferative effect of dacomitinib in 
both cells was significantly increased by cotreatment of siREV3L in colony 
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formation assays (Figure 4.8B). Furthermore, cotreatment of dacomitinib and 
siREV3L significantly induced cellular senescence, as evidenced by staining of 
a senescence biomarker, acidic β-galactosidase (Figure 4.9). In contrast, 
synergistic antitumor effects were not observed by the combined treatment of 
siREV3L with paclitaxel or cisplatin, suggesting that loss of REV3L function 
may contribute to selective sensitization of tumor cells to dacomitinib (Figure 
4.10). 
Together, these data suggest that REV3L inactivation enhance response to 
dacomitinib by inducing cell cycle arrest and cellular senescence. 
 
 
Figure 4.8: Suppression of REV3l enhances sensitivity to dacomitinib in 
FADU and MSKQLL2 cells. (A) Twenty-four hours after transfection with 
control siRNA and siREV3L, cell were treated with dacomitinib for 72 h. 
Cell cycle distribution was measured by propidium iodide staining and 
subsequent FACS analysis. Error bars indicate mean ± SEM (n = 3). 
*P < 0.05, siREV3L vs. combination of siREV3L and dacomitinib; 
**P < 0.01, siREV3L (or dacomitinib) vs. combination of siREV3L and 
dacomitinib; *** P < 0.001, dacomitinib vs. combination of siREV3L and 
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dacomitinib. (B) Control or siREV3L-transfected FADU and MSKQLL2 
cells were treated with dacomitinib at the indicated concentration for 14 
days before staining with crystal violet. 
 
 
Figure 4.9: Combination of siREV3L and dacomitinib induces senescence in 
FADU and MSKQLL2 cells. After 24 hours of transfection with control 
siRNA and siREV3L, cells were treated with dacomitinib for 72 h. Then, cells 





Figure 4.10. REV3L depletion did not enhance the growth inhibitory effects of 
paclitaxel or cisplatin in head and neck cancer cells. (A) Cells were transfected 
for 24 h with control siRNA or siREV3L, respectively, and were treated with 
or without paclitaxel at the indicated concentration for 14 days. Following the 
treatment, cells were fixed and stained with crystal violet 0.005%. (B) Cells 
were treated with or without cisplatin at the indicated concentration for 14 
days after transfection with control siRNA or siREV3L, respectively. 







4.6 Cotreatment of siREV3L and dacomitinib produced synergistic 
antitumor effects by inhibition of homologous recombination repair 
        In addition to important roles in error-prone TLS in which DNA 
replication bypasses blocking lesions, REV3L has also been implicated in 
promoting repair of DNA DSBs by homologous recombination (HR) (Lange, 
Takata et al. 2011, Sharma, Hicks et al. 2012). EGFR inhibitors have been 
reported to attenuate HR repair of DNA DSBs, resulting in persistent DNA 
damage (Li, Wang et al. 2008, Tanaka, Munshi et al. 2008, Nowsheen, Bonner 
et al. 2011). Therefore, we investigated whether combination of siREV3L and 
dacomitinib can increase nuclear γH2AX foci, which is an in situ marker of 
DNA DSBs. In both cells, treatment with siREV3L alone or dacomitinib alone 
produced modest increase of γH2AX foci. Notably, cotreatment of siREV3L 
and dacomitinib significantly increased γH2AX foci, suggesting the 
significant reduction of HR-mediated DNA DSB repair (Figure 4.11A).  
BRCA1 is an essential component of HR repair of DNA DSBs and the 
nuclear function of BRCA1 is controlled by its subcellular localization 
(Fabbro, Schuechner et al. 2004, Feng, Kachnic et al. 2004). To explore 
inhibition of HR repair, we observed BRCA1 cytoplasmic shuttling upon 
treatment of siREV3L alone, dacomitinib alone or their combination. In both 
cells, the inhibition of REV3L alone modestly increased cytoplasmic 
translocation of BRCA1. Remarkably, cotreatment of siREV3L and 
dacomitinib resulted in significant cytoplasmic translocation of BRCA1, 
preventing BRCA1-induced HR repair (Figure 4.11B). Cytoplasmic retention 
of BRCA1 by cotreatment of siREV3L and dacomitinib was also confirmed by 




Figure 4.11 : Dacomitinib induces persistent DNA damage in REV3L-depleted 
head and neck cancer cells. (A) Cells were transfected with control siRNA or 
siREV3L for 24 h, and treated with DMSO or 1 μM Dacomitinib for 72 h. 
Shown is the percentage of foci-containing cells with >10 foci. The inset 
shows a representative staining of increased γ-H2AX foci (green) in 
siREV3L-transfected cells (bottom panels) compared to control siRNA-
transfected cells (top panels). Cell nuclei were stained with DAPI (blue). 
Error bars indicate mean ± SEM (n = 3). *p < 0.05, **p < 0.01. (B) Under 
immunofluorescence microscopy, subcellular localization of BRCA1 was 
counted as having nuclear staining only, cytoplasmic staining only, or both 
nuclear/cytoplasmic staining. A total of 20 cells were counted per field and 
a total of 10 fields were assessed. Error bars indicate mean ± SEM (n = 3). 
*p < 0.05, siREV3L vs. combination of siREV3L and dacomitinib; 
**p < 0.01, siREV3L vs. combination of siREV3L and dacomitinib; 





Figure 4.12: Dacomitinib translocates BRCA1 from nucleus to cytoplasm in 
REV3L-silenced head and neck cancer cells. Cells were transfected with 
control siRNA or siREV3L for 24h, and were treated with or without 
dacomitinib 1 μM for 72 h. Following the treatment, cells were stained with 
BRCA1 antibody (green) and DAPI (blue), and the subcellular localization of 
BRCA1 was detected by fluorescence microscopy.  
 
         Taken together, these data suggest that the loss of REV3L function and 
dacomitinib treatment synergistically enhanced cytotoxicity via loss of HR 
repair of DNA DSBs.   
 
4.7 Discussions 
In this study, we performed WES in SCCHN patients treated with 
dacomitinib to identify potential predictive biomarkers. Extensive exome-wide 
studies in SCCHN have been reported (Agrawal, Frederick et al. 2011, 
Stransky, Egloff et al. 2011, Cancer Genome Atlas 2015), uncovering 
recurrent somatic mutations in TP53 (47-72%), NOTCH1 (14-19%), CDKN2A 
(9-22%), PIK3CA (6-21%), FBXW7 (5%), HRAS (4-8%) and CASP8 (8%). 
However, most patient samples selected for sequencing are chemotherapy-
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naïve tumors, rendering the evaluation of chemotherapy effects on the cancer 
genomes difficult. Based on the hypothesis that cisplatin treatment may drive 
the mutational process and thereby promote tumor progression, we have 
profiled the complete genetic alterations in 18 cisplatin-pretreated SCCHN.  
Our study suggests that REV3L may be a novel driver gene in SCCHN, 
the mutations of which are selected during cisplatin treatment and these 
mutations confer sensitivity to dacomitinib treatment. We offered the 
following evidences to support this conclusion. First, somatic mutation of 
REV3L is highly prevalent in our cohort of cisplatin-treated patients (3/18; 
16.7%) compared to the treatment-naïve TCGA (8/279; 2.9%). This frequency 
is even higher when considering only the subset of cisplatin-resistant and 
dacomitinib-sensitive patients (3/7; 42.9%). Second, we independently 
confirmed all three REV3L mutations using Sanger sequencing in cisplatin-
treated tumor samples but not in the cisplatin-naive samples from the same 
patients. This suggests that REV3L mutations or clonal selection is a 
consequence of cisplatin treatment. Third, we observed a significant increase 
in sensitivity to dacomitinib in two dacomitinib-resistant cell lines upon 
REV3L silencing. Thus, REV3L mutational status may be a promising 
predictive biomarker for dacomitinib in SCCHN. 
REV3L is the gene encoding for the catalytic subunit of DNA 
polymerase zeta, an essential component in DNA translesion synthesis. DNA 
polymerase zeta has the remarkable abilities to efficiently bypass DNA lesions 
formed by cisplatin, UV, tobacco, AP site and others (Shachar, Ziv et al. 2009, 
Takata and Wood 2009). These properties allow cells with severely damaged 
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DNA to survive, albeit at the cost of introducing large amount of mutations 
due to the error prone replication activity of DNA polymerase zeta. Therefore, 
somatic inactivation of REV3L may result in the accumulation of unrepairable 
DNA DSBs, which makes tumor cells vulnerable to dacomitinib-mediated 
inhibition of HR repair (Li, Wang et al. 2008, Knobel, Kotov et al. 2011, 
Nowsheen, Bonner et al. 2011). Indeed, our functional assays indicate that 
REV3L knockdown significantly increased the DNA DSBs, suggesting the loss 
of TLS. Administration of dacomitinib in REV3L-inactivated cells caused 
cytoplasmic retention of BRCA1, suggesting the additional loss of template-
switching pathway.  
Our study may be limited by small sample size. However, we believe 
that our study deserve special recognition due to following reasons. Firstly, all 
patients in our study had been enrolled and treated with dacomitinib in the 
prospective phase II trial (Kim, Kwon et al. 2015). Therefore, our study 
provides cleaner datasets and less selection bias. Secondly, all the tumor 
specimens were taken for exome sequencing immediately before the treatment 
of dacomitinib. Rebiopsy in heavily-pretreated cancer patients, despite its 
potential usefulness, poses significant clinical challenges due to patients’ 
reluctance to high-risk procedures, patient’s comorbidities and lack of 
biopsible tumor lesion (Brown, Wendler et al. 2008). Furthermore, genomic 
analysis of freshly rebiopsied tumors can be challenging due to limited amount 
of DNA extracted from the tumor tissues. These challenges explain why there 
have been few reports of comprehensive genomic study in metastatic cancer 
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patients. Because of aforementioned reasons, there are a number of hurdles to 




Chapter 5: Conclusion 
 The present thesis aimed at utilizing whole exome sequencing 
technique to identify and associate novel driver genes with specific clinical 
phenotypes. This goal was achieved by identifying important questions related 
to the clinical management of GIST and R/M SCCHN. Patient samples were 
then carefully selected for exome sequencing to gain insights into the genetic 
determinants to these tumor phenotypes. 
In the first part of the result (Chapter 3), we identified SETD2 
mutations as a likely pathogenic event driving GIST progression. This is 
achieved by performing whole exome sequencing on tumor samples from 
GIST patients, comprehensively cataloguing the somatic mutational events 
and comparing the patterns of mutational events imprinted on the cancer 
genomes from high- and low-risk patients. 
 The identified genetic difference between high- and low-risk GISTs 
tumor was then further validated in a larger cohort of 120 independent GIST 
patients. This largest to date analysis of GIST genomic data provided the first 
data of the involvement of SETD2 in GIST pathogenesis. Further evidences 
supporting the role of SETD2 mutation in GIST were acquired by examining 
the DNA methylation, RNA transcription and protein expression profiles in 
SETD2-mutant and SETD2-wildtype GISTs. Finally, the functional role of 
SETD2 mutations was confirmed using in vitro experiments where the 
relationship of SETD2 loss and DNA damage was assessed. 
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 From a translational medicine point of view, risk stratification is an 
important part of GIST management. For localized GIST, risk stratification 
strategies are currently based on several clinic-pathological criteria (Fletcher, 
Berman et al. 2002, Miettinen and Lasota 2006, Joensuu 2008). Due to the 
lack of validated biomarkers, molecular data is not utilized. The finding from 
this thesis, if independently validated, may potentially be utilized as molecular 
biomarker of high-risk GISTs. 
In the second part of this thesis (Chapter 4), we performed whole 
exome sequencing in cisplatin-pretreated R/M SCCHN to identify potential 
predictive markers for dacomitinib, a second generation EGFR TKI.  Our 
study suggests that REV3L mutations may be selected during cisplatin 
treatment and contribute to better response to dacomitinib. This hypothesis is 
supported by the fact that all REV3L mutations were observed in cisplatin-
pretreated samples but not in cisplatin-naïve samples. In functional assays, we 
demonstrated that REV3L loss-of-function dramatically enhances the 
sensitivity of SCCHN cells to dacomitinib by the loss of both translesion 
synthesis and homologous recombination pathways.  
These findings have potential implications. EGFR-targeted therapy has 
demonstrated only marginal benefit in unselected patients (Soulieres, Senzer et 
al. 2004, Vermorken, Trigo et al. 2007, Stewart, Cohen et al. 2009, Abdul 
Razak, Soulieres et al. 2013, Kim, Kwon et al. 2015). Therefore, the selection 
of patients who are most likely to respond to EGFR-targeted agents including 
dacomitinib is an important challenge. In our study, we observed recurrent 
REV3L somatic inactivations in dacomitinib-sensitive tumors at a frequency 
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not attributable to chance alone. Importantly, our mechanistic study supports 
the hypothesis that REV3L inactivation enhanced dacomitinib efficacy and 
provide a rationale for this observation.  
This thesis has a number of shortcomings pertaining to the 
experimental approach and generated data. With regards to experimental 
approach, the study focused on the protein-coding region of the human 
genome, although this region comprise of less than 2% of the entire human 
genome. Therefore, genetic mutations occurring outside of the targeted 
regions that may influence cancer progression may have been overlooked in 
this study.  
 The cohort of patients examined in this study is relatively small, with a 
discovery cohort of 14 GIST and 18 R/M SCCHN patients. This limitation 
restricts our discovery power of low-frequency mutational events that may 
also be responsible for cancer progression. Nevertheless, despite these 
limitations, these studies did allow for the identification of novel mutational 
events in both tumor types. 
 The present study undertaken here is in no way an end in itself, but 
requires further refinement and improvement. This should include the 
generation of more molecular data from large group of patients to discover 
rare mutations in the long tail of genetic alterations that may drive cancer 
pathogenesis. The use of complementary technology such as whole genome 
sequencing may also uncover mutations in the non-coding region of the 
human genome missed in the current study. 
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Taken together, this thesis provides one of the first roadmaps of 
genetic events underlying the progression of GIST and R/M SCCHN. The 
results reveal novel candidate driver genes delineating important transition 
points between tumors with different clinical phenotypes, with potential 
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